{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:08:51Z","timestamp":1795172931855,"version":"4.10.3"},"reference-count":346,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases PE00000007"],"award-info":[{"award-number":["NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases PE00000007"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["INF-ACT"],"award-info":[{"award-number":["INF-ACT"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Influenza viruses still represent a great concern for Public Health by causing yearly seasonal epidemics and occasionally worldwide pandemics. Moreover, spillover events at the animal-human interface are becoming more frequent nowadays, also involving animal species not previously found as reservoirs. To restrict the effects of influenza virus epidemics, especially in at-risk population, and to prepare a drug arsenal for possible future pandemics, researchers worldwide have been working on the development of antiviral strategies since the 80\u2019s of the last century. One of the main obstacles is the considerable genomic variability of influenza viruses, which constantly poses the issues of drug-resistance emergence and immune evasion. This review summarizes the approved therapeutics for clinical management of influenza, promising new anti-flu compounds and monoclonal antibodies currently undergoing clinical evaluation, and molecules with efficacy against influenza virus in preclinical studies. Moreover, we discuss some innovative anti-influenza therapeutic approaches such as combination therapies and targeted protein degradation. Given the limited number of drugs approved for influenza treatment, there is a still strong need for novel potent anti-influenza drugs endowed with a high barrier to drug resistance and broad-spectrum activity against influenza viruses of animal origin that may be responsible of future large outbreaks and pandemics.<\/jats:p>","DOI":"10.1007\/s00018-025-05611-1","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:39:45Z","timestamp":1739439585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches"],"prefix":"10.1007","volume":"82","author":[{"given":"Anna","family":"Bonomini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Mercorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-861X","authenticated-orcid":false,"given":"Arianna","family":"Loregian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"5611_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(22)00982-5","volume":"400","author":"TM Uyeki","year":"2022","unstructured":"Uyeki TM, Hui DS, Zambon M et al (2022) Influenza. Lancet 400:693\u2013706. https:\/\/doi.org\/10.1016\/S0140-6736(22)00982-5","journal-title":"Lancet"},{"key":"5611_CR2","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1073\/pnas.90.9.4171","volume":"90","author":"JW Drake","year":"1993","unstructured":"Drake JW (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90:4171\u20134175. https:\/\/doi.org\/10.1073\/pnas.90.9.4171","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.chom.2010.05.009","volume":"7","author":"JK Taubenberger","year":"2010","unstructured":"Taubenberger JK, Kash JC (2010) Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7:440\u2013451. https:\/\/doi.org\/10.1016\/j.chom.2010.05.009","journal-title":"Cell Host Microbe"},{"key":"5611_CR4","doi-asserted-by":"publisher","first-page":"103998","DOI":"10.1016\/j.cellimm.2019.103998","volume":"348","author":"HL Dugan","year":"2020","unstructured":"Dugan HL, Henry C, Wilson PC (2020) Aging and influenza vaccine-induced immunity. Cell Immunol 348:103998. https:\/\/doi.org\/10.1016\/j.cellimm.2019.103998","journal-title":"Cell Immunol"},{"key":"5611_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/vaccines10050800","volume":"10","author":"KC See","year":"2022","unstructured":"See KC (2022) Vaccination for the prevention of infection among immunocompromised patients: a concise review of recent systematic reviews. Vaccines 10:800. https:\/\/doi.org\/10.3390\/vaccines10050800","journal-title":"Vaccines"},{"key":"5611_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMp1714916","volume":"378","author":"CI Paules","year":"2018","unstructured":"Paules CI, Sullivan SG, Subbarao K, Fauci AS (2018) Chasing seasonal influenza\u2014the need for a universal Influenza vaccine. N Engl J Med 378:7\u20139. https:\/\/doi.org\/10.1056\/NEJMp1714916","journal-title":"N Engl J Med"},{"key":"5611_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer F, Smith GJD, Fouchier RAM et al (2018) Influenza. Nat Rev Dis Primer 4:3. https:\/\/doi.org\/10.1038\/s41572-018-0002-y","journal-title":"Nat Rev Dis Primer"},{"issue":"Suppl 1","key":"5611_CR8","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1016\/j.vaccine.2020.09.004","volume":"39","author":"JKH Lee","year":"2021","unstructured":"Lee JKH, Lam GKL, Shin T et al (2021) Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis. Vaccine 39(Suppl 1):A24\u2013A35. https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.004","journal-title":"Vaccine"},{"key":"5611_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/fcp.12609","volume":"35","author":"BC Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves BC, Lopes Barbosa MG, Silva Olak AP et al (2021) Antiviral therapies: advances and perspectives. Fundam Clin Pharmacol 35:305\u2013320. https:\/\/doi.org\/10.1111\/fcp.12609","journal-title":"Fundam Clin Pharmacol"},{"key":"5611_CR10","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1074\/jbc.R500020200","volume":"281","author":"LH Pinto","year":"2006","unstructured":"Pinto LH, Lamb RA (2006) The M2 proton channels of influenza A and B viruses. J Biol Chem 281:8997\u20139000. https:\/\/doi.org\/10.1074\/jbc.R500020200","journal-title":"J Biol Chem"},{"key":"5611_CR11","doi-asserted-by":"publisher","first-page":"116172","DOI":"10.1016\/j.ejmech.2024.116172","volume":"267","author":"G Kumar","year":"2024","unstructured":"Kumar G, Sakharam KA (2024) Tackling Influenza A virus by M2 ion channel blockers: latest progress and limitations. Eur J Med Chem 267:116172. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116172","journal-title":"Eur J Med Chem"},{"key":"5611_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1086\/518936","volume":"196","author":"VM Deyde","year":"2007","unstructured":"Deyde VM, Xu X, Bright RA et al (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196:249\u2013257. https:\/\/doi.org\/10.1086\/518936","journal-title":"J Infect Dis"},{"key":"5611_CR13","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1086\/504723","volume":"193","author":"C-L Cheung","year":"2006","unstructured":"Cheung C-L, Rayner JM, Smith GJD et al (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193:1626\u20131629. https:\/\/doi.org\/10.1086\/504723","journal-title":"J Infect Dis"},{"key":"5611_CR14","doi-asserted-by":"publisher","first-page":"e0119115","DOI":"10.1371\/journal.pone.0119115","volume":"10","author":"G Dong","year":"2015","unstructured":"Dong G, Peng C, Luo J et al (2015) Adamantane-resistant influenza a viruses in the world (1902\u20132013): frequency and distribution of M2 gene mutations. PLoS ONE 10:e0119115. https:\/\/doi.org\/10.1371\/journal.pone.0119115","journal-title":"PLoS ONE"},{"key":"5611_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/303041a0","volume":"303","author":"PM Colman","year":"1983","unstructured":"Colman PM, Varghese JN, Laver WG (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41\u201344. https:\/\/doi.org\/10.1038\/303041a0","journal-title":"Nature"},{"key":"5611_CR16","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/S0140-6736(98)00087-7","volume":"352","author":"RC Read","year":"1998","unstructured":"Read RC (1998) Treating influenza with zanamivir. Lancet 352:1872\u20131873. https:\/\/doi.org\/10.1016\/S0140-6736(98)00087-7","journal-title":"Lancet"},{"key":"5611_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1177\/1060028020963616","volume":"55","author":"D Slain","year":"2021","unstructured":"Slain D (2021) Intravenous Zanamivir: A viable option for critically Ill patients with influenza. Ann Pharmacother 55:760\u2013771. https:\/\/doi.org\/10.1177\/1060028020963616","journal-title":"Ann Pharmacother"},{"key":"5611_CR18","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJM199910283411802","volume":"341","author":"FG Hayden","year":"1999","unstructured":"Hayden FG, Atmar RL, Schilling M et al (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341:1336\u20131343. https:\/\/doi.org\/10.1056\/NEJM199910283411802","journal-title":"N Engl J Med"},{"key":"5611_CR19","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40265-018-0981-8","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ (2018) Peramivir: a review in uncomplicated influenza. Drugs 78:1363\u20131370. https:\/\/doi.org\/10.1007\/s40265-018-0981-8","journal-title":"Drugs"},{"key":"5611_CR20","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1086\/656802","volume":"51","author":"A Watanabe","year":"2010","unstructured":"Watanabe A, Chang S-C, Kim MJ et al (2010) Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51:1167\u20131175. https:\/\/doi.org\/10.1086\/656802","journal-title":"Clin Infect Dis"},{"key":"5611_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/cid\/ciw255","volume":"63","author":"S Kashiwagi","year":"2016","unstructured":"Kashiwagi S, Watanabe A, Ikematsu H et al (2016) Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza. Clin Infect Dis 63:330\u2013337. https:\/\/doi.org\/10.1093\/cid\/ciw255","journal-title":"Clin Infect Dis"},{"key":"5611_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","volume":"98","author":"M Samson","year":"2013","unstructured":"Samson M, Pizzorno A, Abed Y, Boivin G (2013) Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 98:174\u2013185. https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.014","journal-title":"Antiviral Res"},{"key":"5611_CR23","doi-asserted-by":"publisher","first-page":"104718","DOI":"10.1016\/j.antiviral.2020.104718","volume":"175","author":"E Takashita","year":"2020","unstructured":"Takashita E, Daniels RS, Fujisaki S et al (2020) Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017\u20132018. Antiviral Res 175:104718. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104718","journal-title":"Antiviral Res"},{"key":"5611_CR24","doi-asserted-by":"publisher","first-page":"9427","DOI":"10.1128\/JVI.00373-10","volume":"84","author":"AC Hurt","year":"2010","unstructured":"Hurt AC, Nor\u2019e SS, McCaw JM, et al (2010) Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol 84:9427\u20139438. https:\/\/doi.org\/10.1128\/JVI.00373-10","journal-title":"J Virol"},{"key":"5611_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/135965350400900404","volume":"9","author":"Y Abed","year":"2004","unstructured":"Abed Y, Goyette N, Boivin G (2004) A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A\/H1N1 virus. Antivir Ther 9:577\u2013581","journal-title":"Antivir Ther"},{"key":"5611_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jcv.2009.11.003","volume":"47","author":"T Baranovich","year":"2010","unstructured":"Baranovich T, Saito R, Suzuki Y et al (2010) Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008\u20132009 season. J Clin Virol 47:23\u201328. https:\/\/doi.org\/10.1016\/j.jcv.2009.11.003","journal-title":"J Clin Virol"},{"key":"5611_CR27","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1016\/j.vaccine.2009.07.017","volume":"27","author":"PJ Collins","year":"2009","unstructured":"Collins PJ, Haire LF, Lin YP et al (2009) Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27:6317\u20136323. https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.017","journal-title":"Vaccine"},{"key":"5611_CR28","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.antiviral.2022.105281","volume":"200","author":"EA Govorkova","year":"2022","unstructured":"Govorkova EA, Takashita E, Daniels RS et al (2022) Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018\u20132020. Antiviral Res 200:105281. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105281","journal-title":"Antiviral Res"},{"key":"5611_CR29","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1002\/jmv.27870","volume":"94","author":"W Zhang","year":"2022","unstructured":"Zhang W, Xu H, Guan S et al (2022) Frequency and distribution of H1N1 influenza A viruses with oseltamivir-resistant mutations worldwide before and after the 2009 pandemic. J Med Virol 94:4406\u20134416. https:\/\/doi.org\/10.1002\/jmv.27870","journal-title":"J Med Virol"},{"key":"5611_CR30","doi-asserted-by":"publisher","first-page":"e1004065","DOI":"10.1371\/journal.ppat.1004065","volume":"10","author":"J Butler","year":"2014","unstructured":"Butler J, Hooper KA, Petrie S et al (2014) Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog 10:e1004065. https:\/\/doi.org\/10.1371\/journal.ppat.1004065","journal-title":"PLoS Pathog"},{"key":"5611_CR31","doi-asserted-by":"publisher","first-page":"20666","DOI":"10.2807\/1560-7917.es2014.19.1.20666","volume":"19","author":"E Takashita","year":"2014","unstructured":"Takashita E, Ejima M, Itoh R et al (2014) A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill 19:20666. https:\/\/doi.org\/10.2807\/1560-7917.es2014.19.1.20666","journal-title":"Euro Surveill"},{"key":"5611_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/infdis\/jis337","volume":"206","author":"AC Hurt","year":"2012","unstructured":"Hurt AC, Hardie K, Wilson NJ et al (2012) Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 206:148\u2013157. https:\/\/doi.org\/10.1093\/infdis\/jis337","journal-title":"J Infect Dis"},{"key":"5611_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1590\/0074-02760140330","volume":"110","author":"Lopes e Souza TM, Fintelman-Rodrigu","year":"2015","unstructured":"Lopes e Souza TM, Fintelman-Rodrigues N, Resende PC, et al (2015) Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance. Mem Inst Oswaldo Cruz 110:101\u2013105. https:\/\/doi.org\/10.1590\/0074-02760140330","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"5611_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-3-662-06099-5_4","volume":"283","author":"G Neumann","year":"2004","unstructured":"Neumann G, Brownlee GG, Fodor E, Kawaoka Y (2004) Orthomyxovirus replication, transcription, and polyadenylation. Curr Top Microbiol Immunol 283:121\u2013143. https:\/\/doi.org\/10.1007\/978-3-662-06099-5_4","journal-title":"Curr Top Microbiol Immunol"},{"key":"5611_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K et al (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446\u2013454. https:\/\/doi.org\/10.1016\/j.antiviral.2013.09.015","journal-title":"Antiviral Res"},{"key":"5611_CR36","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1128\/JVI.02346-12","volume":"87","author":"T Baranovich","year":"2013","unstructured":"Baranovich T, Wong S-S, Armstrong J et al (2013) T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741\u20133751. https:\/\/doi.org\/10.1128\/JVI.02346-12","journal-title":"J Virol"},{"key":"5611_CR37","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1128\/AAC.00649-13","volume":"57","author":"H Sangawa","year":"2013","unstructured":"Sangawa H, Komeno T, Nishikawa H et al (2013) Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57:5202\u20135208. https:\/\/doi.org\/10.1128\/AAC.00649-13","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR38","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 209:107512. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107512","journal-title":"Pharmacol Ther"},{"key":"5611_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/jcm10020273","volume":"10","author":"R \u0141agocka","year":"2021","unstructured":"\u0141agocka R, Dziedziejko V, K\u0142os P, Pawlik A (2021) Favipiravir in therapy of viral infections. J Clin Med 10:273. https:\/\/doi.org\/10.3390\/jcm10020273","journal-title":"J Clin Med"},{"key":"5611_CR40","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.1811345115","volume":"115","author":"DH Goldhill","year":"2018","unstructured":"Goldhill DH, te Velthuis AJW, Fletcher RA et al (2018) The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A 115:11613\u201311618. https:\/\/doi.org\/10.1073\/pnas.1811345115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR41","doi-asserted-by":"publisher","first-page":"e1008937","DOI":"10.1371\/journal.ppat.1008937","volume":"17","author":"DH Goldhill","year":"2021","unstructured":"Goldhill DH, Yan A, Frise R et al (2021) Favipiravir-resistant influenza A virus shows potential for transmission. PLoS Pathog 17:e1008937. https:\/\/doi.org\/10.1371\/journal.ppat.1008937","journal-title":"PLoS Pathog"},{"key":"5611_CR42","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nature07745","volume":"458","author":"A Dias","year":"2009","unstructured":"Dias A, Bouvier D, Cr\u00e9pin T et al (2009) The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458:914\u2013918. https:\/\/doi.org\/10.1038\/nature07745","journal-title":"Nature"},{"key":"5611_CR43","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","volume":"78","author":"Y-A Heo","year":"2018","unstructured":"Heo Y-A (2018) Baloxavir: first global approval. Drugs 78:693\u2013697. https:\/\/doi.org\/10.1007\/s40265-018-0899-1","journal-title":"Drugs"},{"key":"5611_CR44","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1056\/NEJMe2022702","volume":"383","author":"TM Uyeki","year":"2020","unstructured":"Uyeki TM (2020) Baloxavir for postexposure prophylaxis against Influenza in households. N Engl J Med 383:389\u2013390. https:\/\/doi.org\/10.1056\/NEJMe2022702","journal-title":"N Engl J Med"},{"key":"5611_CR45","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","volume":"8","author":"S Omoto","year":"2018","unstructured":"Omoto S, Speranzini V, Hashimoto T et al (2018) Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 8:9633. https:\/\/doi.org\/10.1038\/s41598-018-27890-4","journal-title":"Sci Rep"},{"key":"5611_CR46","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1021\/acs.biochem.3c00536","volume":"63","author":"AJ Kohlbrand","year":"2024","unstructured":"Kohlbrand AJ, Stokes RW, Sankaran B, Cohen SM (2024) Structural studies of inhibitors with clinically relevant influenza endonuclease variants. Biochemistry 63:264\u2013272. https:\/\/doi.org\/10.1021\/acs.biochem.3c00536","journal-title":"Biochemistry"},{"key":"5611_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/infdis\/jiz244","volume":"221","author":"T Uehara","year":"2020","unstructured":"Uehara T, Hayden FG, Kawaguchi K et al (2020) Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 221:346\u2013355. https:\/\/doi.org\/10.1093\/infdis\/jiz244","journal-title":"J Infect Dis"},{"key":"5611_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4149\/av_2018_211","volume":"62","author":"D Cocking","year":"2018","unstructured":"Cocking D, Cinatl J, Boltz DA et al (2018) Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol 62:191\u2013195. https:\/\/doi.org\/10.4149\/av_2018_211","journal-title":"Acta Virol"},{"key":"5611_CR49","doi-asserted-by":"publisher","first-page":"e02605","DOI":"10.1128\/AAC.02605-20","volume":"65","author":"AJW Te Velthuis","year":"2021","unstructured":"Te Velthuis AJW, Zubkova TG, Shaw M et al (2021) Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity. Antimicrob Agents Chemother 65:e02605-e2620. https:\/\/doi.org\/10.1128\/AAC.02605-20","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1073\/pnas.1617020114","volume":"114","author":"RU Kadam","year":"2017","unstructured":"Kadam RU, Wilson IA (2017) Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A 114:206\u2013214. https:\/\/doi.org\/10.1073\/pnas.1617020114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/v10040184","volume":"10","author":"J Haviernik","year":"2018","unstructured":"Haviernik J, \u0160tef\u00e1nik M, Fojt\u00edkov\u00e1 M et al (2018) Arbidol (Umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne Flaviviruses. Viruses 10:184. https:\/\/doi.org\/10.3390\/v10040184","journal-title":"Viruses"},{"key":"5611_CR52","doi-asserted-by":"publisher","first-page":"e02185","DOI":"10.1128\/JVI.02185-18","volume":"93","author":"CE Hulseberg","year":"2019","unstructured":"Hulseberg CE, F\u00e9n\u00e9ant L, Szyma\u0144ska-de Wijs KM et al (2019) Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol 93:e02185-e2218. https:\/\/doi.org\/10.1128\/JVI.02185-18","journal-title":"J Virol"},{"key":"5611_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","volume":"6","author":"X Wang","year":"2020","unstructured":"Wang X, Cao R, Zhang H et al (2020) The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 6:28. https:\/\/doi.org\/10.1038\/s41421-020-0169-8","journal-title":"Cell Discov"},{"key":"5611_CR54","doi-asserted-by":"publisher","first-page":"105785","DOI":"10.1016\/j.antiviral.2023.105785","volume":"221","author":"X Sun","year":"2024","unstructured":"Sun X, Ma H, Wang X et al (2024) Broadly neutralizing antibodies to combat influenza virus infection. Antiviral Res 221:105785. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105785","journal-title":"Antiviral Res"},{"key":"5611_CR55","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1126\/science.1171491","volume":"324","author":"DC Ekiert","year":"2009","unstructured":"Ekiert DC, Bhabha G, Elsliger M-A et al (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324:246\u2013251. https:\/\/doi.org\/10.1126\/science.1171491","journal-title":"Science"},{"key":"5611_CR56","doi-asserted-by":"publisher","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","volume":"3","author":"M Throsby","year":"2008","unstructured":"Throsby M, van den Brink E, Jongeneelen M et al (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3:e3942. https:\/\/doi.org\/10.1371\/journal.pone.0003942","journal-title":"PLoS ONE"},{"key":"5611_CR57","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1204839","volume":"333","author":"DC Ekiert","year":"2011","unstructured":"Ekiert DC, Friesen RHE, Bhabha G et al (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843\u2013850. https:\/\/doi.org\/10.1126\/science.1204839","journal-title":"Science"},{"key":"5611_CR58","doi-asserted-by":"publisher","first-page":"e4260","DOI":"10.1093\/cid\/ciaa1725","volume":"73","author":"A Han","year":"2021","unstructured":"Han A, Czajkowski L, Rosas LA et al (2021) Safety and efficacy of CR6261 in an Influenza A H1N1 healthy human challenge model. Clin Infect Dis 73:e4260\u2013e4268. https:\/\/doi.org\/10.1093\/cid\/ciaa1725","journal-title":"Clin Infect Dis"},{"key":"5611_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.chom.2013.06.004","volume":"14","author":"G Nakamura","year":"2013","unstructured":"Nakamura G, Chai N, Park S et al (2013) An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14:93\u2013103. https:\/\/doi.org\/10.1016\/j.chom.2013.06.004","journal-title":"Cell Host Microbe"},{"key":"5611_CR60","doi-asserted-by":"publisher","first-page":"e01154","DOI":"10.1128\/AAC.01154-17","volume":"61","author":"JM McBride","year":"2017","unstructured":"McBride JM, Lim JJ, Burgess T et al (2017) Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model. Antimicrob Agents Chemother 61:e01154-e1217. https:\/\/doi.org\/10.1128\/AAC.01154-17","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR61","doi-asserted-by":"publisher","first-page":"e00352","DOI":"10.1128\/AAC.00352-20","volume":"64","author":"JJ Lim","year":"2020","unstructured":"Lim JJ, Nilsson AC, Silverman M et al (2020) A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A virus infection. Antimicrob Agents Chemother 64:e00352-e420. https:\/\/doi.org\/10.1128\/AAC.00352-20","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR62","doi-asserted-by":"publisher","first-page":"ofab630","DOI":"10.1093\/ofid\/ofab630","volume":"9","author":"JJ Lim","year":"2022","unstructured":"Lim JJ, Dar S, Venter D et al (2022) A Phase 2 randomized, double-blind, placebo-controlled trial of the monoclonal antibody MHAA4549A in patients with acute uncomplicated influenza a infection. Open Forum Infect Dis 9:ofab630. https:\/\/doi.org\/10.1093\/ofid\/ofab630","journal-title":"Open Forum Infect Dis"},{"key":"5611_CR63","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","volume":"166","author":"NL Kallewaard","year":"2016","unstructured":"Kallewaard NL, Corti D, Collins PJ et al (2016) Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166:596\u2013608. https:\/\/doi.org\/10.1016\/j.cell.2016.05.073","journal-title":"Cell"},{"key":"5611_CR64","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/infdis\/jix292","volume":"216","author":"CI Paules","year":"2017","unstructured":"Paules CI, Lakdawala S, McAuliffe JM et al (2017) The hemagglutinin a stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. J Infect Dis 216:356\u2013365. https:\/\/doi.org\/10.1093\/infdis\/jix292","journal-title":"J Infect Dis"},{"key":"5611_CR65","doi-asserted-by":"publisher","first-page":"e00694","DOI":"10.1128\/AAC.00694-18","volume":"62","author":"SO Ali","year":"2018","unstructured":"Ali SO, Takas T, Nyborg A et al (2018) Evaluation of MEDI8852, an anti-influenza a monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob Agents Chemother 62:e00694-e718. https:\/\/doi.org\/10.1128\/AAC.00694-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR66","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01273-23","volume":"68","author":"D Plotnik","year":"2024","unstructured":"Plotnik D, Sager JE, Aryal M et al (2024) A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrob Agents Chemother 68:e0127323. https:\/\/doi.org\/10.1128\/aac.01273-23","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR67","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/AAC.02457-15","volume":"60","author":"T Baranovich","year":"2016","unstructured":"Baranovich T, Jones JC, Russier M et al (2016) The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome. Antimicrob Agents Chemother 60:2118\u20132131. https:\/\/doi.org\/10.1128\/AAC.02457-15","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR68","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","volume":"40","author":"E Hershberger","year":"2019","unstructured":"Hershberger E, Sloan S, Narayan K et al (2019) Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine 40:574\u2013582. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.051","journal-title":"EBioMedicine"},{"key":"5611_CR69","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.antiviral.2020.104763","volume":"184","author":"SE Sloan","year":"2020","unstructured":"Sloan SE, Szretter KJ, Sundaresh B et al (2020) Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral Res 184:104763. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104763","journal-title":"Antiviral Res"},{"key":"5611_CR70","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3390\/v12091053","volume":"12","author":"NC Wu","year":"2020","unstructured":"Wu NC, Wilson IA (2020) Structural biology of influenza hemagglutinin: an amaranthine adventure. Viruses 12:1053. https:\/\/doi.org\/10.3390\/v12091053","journal-title":"Viruses"},{"key":"5611_CR71","doi-asserted-by":"publisher","first-page":"e0236172","DOI":"10.1371\/journal.pone.0236172","volume":"15","author":"KS Yi","year":"2020","unstructured":"Yi KS, Choi J-A, Kim P et al (2020) Broader neutralization of CT-P27 against influenza A subtypes by combining two human monoclonal antibodies. PLoS ONE 15:e0236172. https:\/\/doi.org\/10.1371\/journal.pone.0236172","journal-title":"PLoS ONE"},{"key":"5611_CR72","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.bbamem.2014.04.015","volume":"1838","author":"H Badani","year":"2014","unstructured":"Badani H, Garry RF, Wimley WC (2014) Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity. Biochim Biophys Acta 1838:2180\u20132197. https:\/\/doi.org\/10.1016\/j.bbamem.2014.04.015","journal-title":"Biochim Biophys Acta"},{"key":"5611_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bcp.13405","volume":"84","author":"JH Beigel","year":"2018","unstructured":"Beigel JH, Voell J, Mu\u00f1oz P et al (2018) Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1\/M2 translation. Br J Clin Pharmacol 84:25. https:\/\/doi.org\/10.1111\/bcp.13405","journal-title":"Br J Clin Pharmacol"},{"key":"5611_CR74","doi-asserted-by":"publisher","first-page":"12658","DOI":"10.1073\/pnas.0911806107","volume":"107","author":"AG Grandea","year":"2010","unstructured":"Grandea AG, Olsen OA, Cox TC et al (2010) Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 107:12658\u201312663. https:\/\/doi.org\/10.1073\/pnas.0911806107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR75","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","volume":"211","author":"EL Ramos","year":"2015","unstructured":"Ramos EL, Mitcham JL, Koller TD et al (2015) Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 211:1038\u20131044. https:\/\/doi.org\/10.1093\/infdis\/jiu539","journal-title":"J Infect Dis"},{"key":"5611_CR76","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nsmb.1421","volume":"15","author":"D Guilligay","year":"2008","unstructured":"Guilligay D, Tarendeau F, Resa-Infante P et al (2008) The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 15:500\u2013506. https:\/\/doi.org\/10.1038\/nsmb.1421","journal-title":"Nat Struct Mol Biol"},{"key":"5611_CR77","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","volume":"219","author":"RW Finberg","year":"2019","unstructured":"Finberg RW, Lanno R, Anderson D et al (2019) Phase 2b Study of Pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ Trial. J Infect Dis 219:1026\u20131034. https:\/\/doi.org\/10.1093\/infdis\/jiy547","journal-title":"J Infect Dis"},{"key":"5611_CR78","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/ph16030365","volume":"16","author":"X Chen","year":"2023","unstructured":"Chen X, Ma Q, Zhao M et al (2023) Preclinical study of ZSP1273, a potent antiviral inhibitor of cap binding to the PB2 subunit of influenza A polymerase. Pharmaceuticals 16:365. https:\/\/doi.org\/10.3390\/ph16030365","journal-title":"Pharmaceuticals"},{"key":"5611_CR79","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/13543784.2021.1994944","volume":"30","author":"Y Hu","year":"2021","unstructured":"Hu Y, Li H, Wu M et al (2021) Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects. Expert Opin Investig Drugs 30:1159\u20131167. https:\/\/doi.org\/10.1080\/13543784.2021.1994944","journal-title":"Expert Opin Investig Drugs"},{"key":"5611_CR80","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1473-3099(23)00743-0","volume":"24","author":"Z Yang","year":"2024","unstructured":"Yang Z, Li Z, Zhan Y et al (2024) Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis 24:535\u2013545. https:\/\/doi.org\/10.1016\/S1473-3099(23)00743-0","journal-title":"Lancet Infect Dis"},{"key":"5611_CR81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","volume":"167","author":"JH Beigel","year":"2019","unstructured":"Beigel JH, Nam HH, Adams PL et al (2019) Advances in respiratory virus therapeutics\u2014a meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 167:45\u201367. https:\/\/doi.org\/10.1016\/j.antiviral.2019.04.006","journal-title":"Antiviral Res"},{"key":"5611_CR82","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.virs.2023.06.002","volume":"38","author":"D Luo","year":"2023","unstructured":"Luo D, Ye Q, Li R-T et al (2023) PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor. Virol Sin 38:559\u2013567. https:\/\/doi.org\/10.1016\/j.virs.2023.06.002","journal-title":"Virol Sin"},{"key":"5611_CR83","doi-asserted-by":"publisher","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","volume":"169","author":"EJ Mifsud","year":"2019","unstructured":"Mifsud EJ, Hayden FG, Hurt AC (2019) Antivirals targeting the polymerase complex of influenza viruses. Antiviral Res 169:104545. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104545","journal-title":"Antiviral Res"},{"key":"5611_CR84","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3851\/IMP3244","volume":"23","author":"TN Kakuda","year":"2018","unstructured":"Kakuda TN, Yogaratnam J, Rito J et al (2018) Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults. Antivir Ther 23:555\u2013566. https:\/\/doi.org\/10.3851\/IMP3244","journal-title":"Antivir Ther"},{"key":"5611_CR85","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/infdis\/jiy410","volume":"219","author":"J Yogaratnam","year":"2019","unstructured":"Yogaratnam J, Rito J, Kakuda TN et al (2019) Antiviral activity, safety, and pharmacokinetics of AL-794, a novel oral influenza endonuclease inhibitor: results of an influenza human challenge study. J Infect Dis 219:177\u2013185. https:\/\/doi.org\/10.1093\/infdis\/jiy410","journal-title":"J Infect Dis"},{"key":"5611_CR86","doi-asserted-by":"publisher","first-page":"1272466","DOI":"10.3389\/fphar.2023.1272466","volume":"14","author":"S-M Xu","year":"2023","unstructured":"Xu S-M, Chang L-W, Tsai C-Y et al (2023) Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study. Front Pharmacol 14:1272466. https:\/\/doi.org\/10.3389\/fphar.2023.1272466","journal-title":"Front Pharmacol"},{"key":"5611_CR87","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","volume":"47","author":"LJ Stuyver","year":"2003","unstructured":"Stuyver LJ, Whitaker T, McBrayer TR et al (2003) Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 47:244\u2013254. https:\/\/doi.org\/10.1128\/AAC.47.1.244-254.2003","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR88","doi-asserted-by":"publisher","first-page":"e01965","DOI":"10.1128\/JVI.01965-17","volume":"92","author":"N Urakova","year":"2018","unstructured":"Urakova N, Kuznetsova V, Crossman DK et al (2018) \u03b2-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol 92:e01965-e2017. https:\/\/doi.org\/10.1128\/JVI.01965-17","journal-title":"J Virol"},{"key":"5611_CR89","doi-asserted-by":"publisher","first-page":"e01348","DOI":"10.1128\/JVI.01348-19","volume":"93","author":"ML Agostini","year":"2019","unstructured":"Agostini ML, Pruijssers AJ, Chappell JD et al (2019) Small-molecule antiviral \u03b2-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol 93:e01348-e1419. https:\/\/doi.org\/10.1128\/JVI.01348-19","journal-title":"J Virol"},{"key":"5611_CR90","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.3390\/v7122934","volume":"7","author":"O Reynard","year":"2015","unstructured":"Reynard O, Nguyen X-N, Alazard-Dany N et al (2015) Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses 7:6233\u20136240. https:\/\/doi.org\/10.3390\/v7122934","journal-title":"Viruses"},{"key":"5611_CR91","doi-asserted-by":"publisher","first-page":"104597","DOI":"10.1016\/j.antiviral.2019.104597","volume":"171","author":"GR Painter","year":"2019","unstructured":"Painter GR, Bowen RA, Bluemling GR et al (2019) The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res 171:104597. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104597","journal-title":"Antiviral Res"},{"key":"5611_CR92","doi-asserted-by":"publisher","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","volume":"11","author":"M Toots","year":"2019","unstructured":"Toots M, Yoon J-J, Cox RM et al (2019) Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 11:eaax5866. https:\/\/doi.org\/10.1126\/scitranslmed.aax5866","journal-title":"Sci Transl Med"},{"key":"5611_CR93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2020.01.005","volume":"220","author":"M Toots","year":"2020","unstructured":"Toots M, Plemper RK (2020) Next-generation direct-acting influenza therapeutics. Transl Res 220:33\u201342. https:\/\/doi.org\/10.1016\/j.trsl.2020.01.005","journal-title":"Transl Res"},{"key":"5611_CR94","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.virusres.2006.09.013","volume":"124","author":"S Boulo","year":"2007","unstructured":"Boulo S, Akarsu H, Ruigrok RWH, Baudin F (2007) Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. Virus Res 124:12\u201321. https:\/\/doi.org\/10.1016\/j.virusres.2006.09.013","journal-title":"Virus Res"},{"key":"5611_CR95","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.celrep.2019.04.053","volume":"27","author":"W Zheng","year":"2019","unstructured":"Zheng W, Fan W, Zhang S et al (2019) Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral nucleoprotein nuclear export. Cell Rep 27:1875-1885.e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.053","journal-title":"Cell Rep"},{"key":"5611_CR96","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.chest.2016.11.012","volume":"151","author":"IFN Hung","year":"2017","unstructured":"Hung IFN, To KKW, Chan JFW et al (2017) Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb\/III Trial. Chest 151:1069\u20131080. https:\/\/doi.org\/10.1016\/j.chest.2016.11.012","journal-title":"Chest"},{"key":"5611_CR97","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/14787210.2.1.43","volume":"2","author":"CA White","year":"2004","unstructured":"White CA (2004) Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther 2:43\u201349. https:\/\/doi.org\/10.1586\/14787210.2.1.43","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5611_CR98","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","volume":"9","author":"J-F Rossignol","year":"2016","unstructured":"Rossignol J-F (2016) Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 9:227\u2013230. https:\/\/doi.org\/10.1016\/j.jiph.2016.04.001","journal-title":"J Infect Public Health"},{"key":"5611_CR99","doi-asserted-by":"publisher","first-page":"2003725","DOI":"10.1183\/13993003.03725-2020","volume":"58","author":"PRM Rocco","year":"2021","unstructured":"Rocco PRM, Silva PL, Cruz FF et al (2021) Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J 58:2003725. https:\/\/doi.org\/10.1183\/13993003.03725-2020","journal-title":"Eur Respir J"},{"key":"5611_CR100","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1038\/s41598-018-28172-9","volume":"8","author":"S Piacentini","year":"2018","unstructured":"Piacentini S, La Frazia S, Riccio A et al (2018) Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57. Sci Rep 8:10425. https:\/\/doi.org\/10.1038\/s41598-018-28172-9","journal-title":"Sci Rep"},{"key":"5611_CR101","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jinf.2011.08.002","volume":"63","author":"DM Siddiq","year":"2011","unstructured":"Siddiq DM, Koo HL, Adachi JA, Viola GM (2011) Norovirus gastroenteritis successfully treated with nitazoxanide. J Infect 63:394\u2013397. https:\/\/doi.org\/10.1016\/j.jinf.2011.08.002","journal-title":"J Infect"},{"key":"5611_CR102","doi-asserted-by":"publisher","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","volume":"284","author":"JF Rossignol","year":"2009","unstructured":"Rossignol JF, La Frazia S, Chiappa L et al (2009) Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 284:29798\u201329808. https:\/\/doi.org\/10.1074\/jbc.M109.029470","journal-title":"J Biol Chem"},{"key":"5611_CR103","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","volume":"147","author":"D Tilmanis","year":"2017","unstructured":"Tilmanis D, van Baalen C, Oh DY et al (2017) The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antiviral Res 147:142\u2013148. https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.002","journal-title":"Antiviral Res"},{"key":"5611_CR104","doi-asserted-by":"publisher","first-page":"104751","DOI":"10.1016\/j.antiviral.2020.104751","volume":"176","author":"EJ Mifsud","year":"2020","unstructured":"Mifsud EJ, Tilmanis D, Oh DY et al (2020) Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy. Antiviral Res 176:104751. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104751","journal-title":"Antiviral Res"},{"key":"5611_CR105","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","volume":"14","author":"J Haffizulla","year":"2014","unstructured":"Haffizulla J, Hartman A, Hoppers M et al (2014) Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis 14:609\u2013618. https:\/\/doi.org\/10.1016\/S1473-3099(14)70717-0","journal-title":"Lancet Infect Dis"},{"key":"5611_CR106","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/cid\/ciz100","volume":"69","author":"AE Gami\u00f1o-Arroyo","year":"2019","unstructured":"Gami\u00f1o-Arroyo AE, Guerrero ML, McCarthy S et al (2019) Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness. Clin Infect Dis 69:1903\u20131911. https:\/\/doi.org\/10.1093\/cid\/ciz100","journal-title":"Clin Infect Dis"},{"key":"5611_CR107","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1093\/jac\/dku074","volume":"69","author":"AV Ivachtchenko","year":"2014","unstructured":"Ivachtchenko AV, Ivanenkov YA, Mitkin OD et al (2014) Novel oral anti-influenza drug candidate AV5080. J Antimicrob Chemother 69:1892\u20131902. https:\/\/doi.org\/10.1093\/jac\/dku074","journal-title":"J Antimicrob Chemother"},{"key":"5611_CR108","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/ofid\/ofad500.132","volume":"10","author":"J Levin","year":"2023","unstructured":"Levin J, D\u00f6hrmann S, Cole JN et al (2023) In vivo efficacy of CD388, a novel drug Fc-conjugate (DFC), against seasonal subtypes of influenza in prophylaxis in immune competent mice, and in a severe immunodeficient (SCID) Mouse Model. Open Forum Infect Dis 10:500. https:\/\/doi.org\/10.1093\/ofid\/ofad500.132","journal-title":"Open Forum Infect Dis"},{"key":"5611_CR109","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","volume":"26","author":"B Mercorelli","year":"2018","unstructured":"Mercorelli B, Pal\u00f9 G, Loregian A (2018) Drug repurposing for viral infectious diseases: how far are we? Trends Microbiol 26:865\u2013876. https:\/\/doi.org\/10.1016\/j.tim.2018.04.004","journal-title":"Trends Microbiol"},{"key":"5611_CR110","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","volume":"50","author":"MP Malakhov","year":"2006","unstructured":"Malakhov MP, Aschenbrenner LM, Smee DF et al (2006) Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 50:1470\u20131479. https:\/\/doi.org\/10.1128\/AAC.50.4.1470-1479.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR111","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/infdis\/jis622","volume":"206","author":"RB Moss","year":"2012","unstructured":"Moss RB, Hansen C, Sanders RL et al (2012) A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 206:1844\u20131851. https:\/\/doi.org\/10.1093\/infdis\/jis622","journal-title":"J Infect Dis"},{"key":"5611_CR112","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.antiviral.2015.09.008","volume":"123","author":"JM Zenilman","year":"2015","unstructured":"Zenilman JM, Fuchs EJ, Hendrix CW et al (2015) Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antiviral Res 123:114\u2013119. https:\/\/doi.org\/10.1016\/j.antiviral.2015.09.008","journal-title":"Antiviral Res"},{"key":"5611_CR113","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/01.atv.15.5.678","volume":"15","author":"JW Nawrocki","year":"1995","unstructured":"Nawrocki JW, Weiss SR, Davidson MH et al (1995) Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15:678\u2013682. https:\/\/doi.org\/10.1161\/01.atv.15.5.678","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5611_CR114","doi-asserted-by":"publisher","first-page":"9516","DOI":"10.1096\/fj.201900428RR","volume":"33","author":"D Episcopio","year":"2019","unstructured":"Episcopio D, Aminov S, Benjamin S et al (2019) Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus. FASEB J 33:9516\u20139525. https:\/\/doi.org\/10.1096\/fj.201900428RR","journal-title":"FASEB J"},{"key":"5611_CR115","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fimmu.2019.00060","volume":"10","author":"A Pizzorno","year":"2019","unstructured":"Pizzorno A, Terrier O, Nicolas de Lamballerie C et al (2019) Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures. Front Immunol 10:60. https:\/\/doi.org\/10.3389\/fimmu.2019.00060","journal-title":"Front Immunol"},{"key":"5611_CR116","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1128\/AAC.01532-12","volume":"57","author":"O Perwitasari","year":"2013","unstructured":"Perwitasari O, Yan X, Johnson S et al (2013) Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother 57:475\u2013483. https:\/\/doi.org\/10.1128\/AAC.01532-12","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR117","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1124\/dmd.30.1.13","volume":"30","author":"G Hill","year":"2002","unstructured":"Hill G, Cihlar T, Oo C et al (2002) The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 30:13\u201319. https:\/\/doi.org\/10.1124\/dmd.30.1.13","journal-title":"Drug Metab Dispos"},{"key":"5611_CR118","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1128\/AAC.00047-08","volume":"52","author":"M Holodniy","year":"2008","unstructured":"Holodniy M, Penzak SR, Straight TM et al (2008) Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 52:3013\u20133021. https:\/\/doi.org\/10.1128\/AAC.00047-08","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR119","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3389\/fimmu.2017.00550","volume":"8","author":"JV Camp","year":"2017","unstructured":"Camp JV, Jonsson CB (2017) A role for neutrophils in viral respiratory disease. Front Immunol 8:550. https:\/\/doi.org\/10.3389\/fimmu.2017.00550","journal-title":"Front Immunol"},{"key":"5611_CR120","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40360-015-0017-x","volume":"16","author":"BE Miller","year":"2015","unstructured":"Miller BE, Mistry S, Smart K et al (2015) The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)\u2014a selective CXCR2 antagonist\u2014in healthy adult subjects. BMC Pharmacol Toxicol 16:18. https:\/\/doi.org\/10.1186\/s40360-015-0017-x","journal-title":"BMC Pharmacol Toxicol"},{"key":"5611_CR121","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13318-014-0179-8","volume":"39","author":"BE Miller","year":"2014","unstructured":"Miller BE, Smart K, Mistry S et al (2014) The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Eur J Drug Metab Pharmacokinet 39:173\u2013181. https:\/\/doi.org\/10.1007\/s13318-014-0179-8","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"5611_CR122","doi-asserted-by":"publisher","first-page":"1801020","DOI":"10.1183\/13993003.01020-2018","volume":"52","author":"AL Lazaar","year":"2018","unstructured":"Lazaar AL, Miller BE, Tabberer M et al (2018) Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD. Eur Respir J 52:1801020. https:\/\/doi.org\/10.1183\/13993003.01020-2018","journal-title":"Eur Respir J"},{"key":"5611_CR123","doi-asserted-by":"publisher","first-page":"106379","DOI":"10.1016\/j.prostaglandins.2019.106379","volume":"147","author":"P Saxena","year":"2020","unstructured":"Saxena P, Sharma PK, Purohit P (2020) A journey of celecoxib from pain to cancer. Prostaglandins Other Lipid Mediat 147:106379. https:\/\/doi.org\/10.1016\/j.prostaglandins.2019.106379","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"5611_CR124","doi-asserted-by":"publisher","first-page":"e1010481","DOI":"10.1371\/journal.ppat.1010481","volume":"18","author":"P Koszalka","year":"2022","unstructured":"Koszalka P, Subbarao K, Baz M (2022) Preclinical and clinical developments for combination treatment of influenza. PLoS Pathog 18:e1010481. https:\/\/doi.org\/10.1371\/journal.ppat.1010481","journal-title":"PLoS Pathog"},{"key":"5611_CR125","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s00705-018-3852-4","volume":"163","author":"ACY Lee","year":"2018","unstructured":"Lee ACY, To KKW, Zhang AJX et al (2018) Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice. Arch Virol 163:2349\u20132358. https:\/\/doi.org\/10.1007\/s00705-018-3852-4","journal-title":"Arch Virol"},{"key":"5611_CR126","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1097\/00002030-200107270-00006","volume":"15","author":"JA Bartlett","year":"2001","unstructured":"Bartlett JA, DeMasi R, Quinn J et al (2001) Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 15:1369\u20131377. https:\/\/doi.org\/10.1097\/00002030-200107270-00006","journal-title":"AIDS"},{"key":"5611_CR127","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli A, Shaffer A, Sherman A, Kottilil S (2014) Treatment of hepatitis C: a systematic review. JAMA 312:631\u2013640. https:\/\/doi.org\/10.1001\/jama.2014.7085","journal-title":"JAMA"},{"key":"5611_CR128","doi-asserted-by":"publisher","first-page":"e0334721","DOI":"10.1128\/mbio.03347-21","volume":"12","author":"JM White","year":"2021","unstructured":"White JM, Schiffer JT, Bender Ignacio RA et al (2021) Drug combinations as a first line of defense against coronaviruses and other emerging viruses. Bio 12:e0334721. https:\/\/doi.org\/10.1128\/mbio.03347-21","journal-title":"Bio"},{"key":"5611_CR129","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/217856a0","volume":"217","author":"SV Lavrov","year":"1968","unstructured":"Lavrov SV, Eremkina EI, Orlova TG et al (1968) Combined inhibition of influenza virus reproduction in cell culture using interferon and amantadine. Nature 217:856\u2013857. https:\/\/doi.org\/10.1038\/217856a0","journal-title":"Nature"},{"key":"5611_CR130","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1128\/AAC.25.1.53","volume":"25","author":"FG Hayden","year":"1984","unstructured":"Hayden FG, Schlepushkin AN, Pushkarskaya NL (1984) Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 25:53\u201357. https:\/\/doi.org\/10.1128\/AAC.25.1.53","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR131","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1126\/science.177.4050.705","volume":"177","author":"RW Sidwell","year":"1972","unstructured":"Sidwell RW, Huffman JH, Khare GP et al (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705\u2013706. https:\/\/doi.org\/10.1126\/science.177.4050.705","journal-title":"Science"},{"key":"5611_CR132","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.antiviral.2006.01.012","volume":"70","author":"NA Ilyushina","year":"2006","unstructured":"Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70:121\u2013131. https:\/\/doi.org\/10.1016\/j.antiviral.2006.01.012","journal-title":"Antiviral Res"},{"key":"5611_CR133","doi-asserted-by":"publisher","first-page":"e9332","DOI":"10.1371\/journal.pone.0009332","volume":"5","author":"JT Nguyen","year":"2010","unstructured":"Nguyen JT, Hoopes JD, Le MH et al (2010) Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 5:e9332. https:\/\/doi.org\/10.1371\/journal.pone.0009332","journal-title":"PLoS ONE"},{"key":"5611_CR134","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1128\/AAC.41.7.1423","volume":"41","author":"S Shigeta","year":"1997","unstructured":"Shigeta S, Mori S, Watanabe J et al (1997) Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob Agents Chemother 41:1423\u20131427. https:\/\/doi.org\/10.1128\/AAC.41.7.1423","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR135","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000057668","volume":"48","author":"DF Smee","year":"2002","unstructured":"Smee DF, Bailey KW, Morrison AC, Sidwell RW (2002) Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 48:88\u201393. https:\/\/doi.org\/10.1159\/000057668","journal-title":"Chemotherapy"},{"key":"5611_CR136","doi-asserted-by":"publisher","first-page":"e31006","DOI":"10.1371\/journal.pone.0031006","volume":"7","author":"JT Nguyen","year":"2012","unstructured":"Nguyen JT, Smee DF, Barnard DL et al (2012) Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS ONE 7:e31006. https:\/\/doi.org\/10.1371\/journal.pone.0031006","journal-title":"PLoS ONE"},{"key":"5611_CR137","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12879-016-1383-8","volume":"16","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Gao H, Liang W et al (2016) Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study. BMC Infect Dis 16:76. https:\/\/doi.org\/10.1186\/s12879-016-1383-8","journal-title":"BMC Infect Dis"},{"key":"5611_CR138","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S1473-3099(17)30476-0","volume":"17","author":"JH Beigel","year":"2017","unstructured":"Beigel JH, Bao Y, Beeler J et al (2017) Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis 17:1255\u20131265. https:\/\/doi.org\/10.1016\/S1473-3099(17)30476-0","journal-title":"Lancet Infect Dis"},{"key":"5611_CR139","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","volume":"22","author":"D Kumar","year":"2022","unstructured":"Kumar D, Ison MG, Mira J-P et al (2022) Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis 22:718\u2013730. https:\/\/doi.org\/10.1016\/S1473-3099(21)00469-2","journal-title":"Lancet Infect Dis"},{"key":"5611_CR140","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","volume":"221","author":"Y Wang","year":"2020","unstructured":"Wang Y, Fan G, Salam A et al (2020) Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically Ill patients with influenza virus infection. J Infect Dis 221:1688\u20131698. https:\/\/doi.org\/10.1093\/infdis\/jiz656","journal-title":"J Infect Dis"},{"key":"5611_CR141","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/infdis\/jiaa376","volume":"226","author":"B O\u2019Neil","year":"2022","unstructured":"O\u2019Neil B, Ison MG, Hallouin-Bernard MC et al (2022) A Phase 2 Study of Pimodivir (JNJ-63623872) in combination with oseltamivir in elderly and nonelderly adults hospitalized with influenza a infection: OPAL Study. J Infect Dis 226:109\u2013118. https:\/\/doi.org\/10.1093\/infdis\/jiaa376","journal-title":"J Infect Dis"},{"key":"5611_CR142","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jmii.2020.08.017","volume":"54","author":"C-W Lee","year":"2021","unstructured":"Lee C-W, Tai Y-L, Huang L-M et al (2021) Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients. J Microbiol Immunol Infect 54:876\u2013884. https:\/\/doi.org\/10.1016\/j.jmii.2020.08.017","journal-title":"J Microbiol Immunol Infect"},{"key":"5611_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0113892010326373241012061547","volume":"26","author":"S Ghosh","year":"2024","unstructured":"Ghosh S, Chowdhury SR, Rahaman M et al (2024) Revolutionizing influenza treatment: a deep dive into targeted drug delivery systems. Curr Pharm Biotechnol 26:1\u201312. https:\/\/doi.org\/10.2174\/0113892010326373241012061547","journal-title":"Curr Pharm Biotechnol"},{"key":"5611_CR144","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature11414","volume":"489","author":"DC Ekiert","year":"2012","unstructured":"Ekiert DC, Kashyap AK, Steel J et al (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489:526\u2013532. https:\/\/doi.org\/10.1038\/nature11414","journal-title":"Nature"},{"key":"5611_CR145","doi-asserted-by":"publisher","first-page":"17040","DOI":"10.1073\/pnas.1212371109","volume":"109","author":"PS Lee","year":"2012","unstructured":"Lee PS, Yoshida R, Ekiert DC et al (2012) Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A 109:17040\u201317045. https:\/\/doi.org\/10.1073\/pnas.1212371109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR146","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/ncomms4614","volume":"5","author":"PS Lee","year":"2014","unstructured":"Lee PS, Ohshima N, Stanfield RL et al (2014) Receptor mimicry by antibody F045\u2013092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun 5:3614. https:\/\/doi.org\/10.1038\/ncomms4614","journal-title":"Nat Commun"},{"key":"5611_CR147","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","volume":"177","author":"S Bangaru","year":"2019","unstructured":"Bangaru S, Lang S, Schotsaert M et al (2019) A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell 177:1136-1152.e18. https:\/\/doi.org\/10.1016\/j.cell.2019.04.011","journal-title":"Cell"},{"key":"5611_CR148","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.cell.2019.03.048","volume":"177","author":"A Watanabe","year":"2019","unstructured":"Watanabe A, McCarthy KR, Kuraoka M et al (2019) Antibodies to a conserved influenza head interface epitope protect by an igg subtype-dependent mechanism. Cell 177:1124-1135.e16. https:\/\/doi.org\/10.1016\/j.cell.2019.03.048","journal-title":"Cell"},{"key":"5611_CR149","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus C, Laursen NS, Kwaks T et al (2012) Highly conserved protective epitopes on influenza B viruses. Science 337:1343\u20131348. https:\/\/doi.org\/10.1126\/science.1222908","journal-title":"Science"},{"key":"5611_CR150","doi-asserted-by":"publisher","first-page":"eaam5752","DOI":"10.1126\/scitranslmed.aam5752","volume":"9","author":"C Shen","year":"2017","unstructured":"Shen C, Chen J, Li R et al (2017) A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci Transl Med 9:eaam5752. https:\/\/doi.org\/10.1126\/scitranslmed.aam5752","journal-title":"Sci Transl Med"},{"key":"5611_CR151","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nsmb.1566","volume":"16","author":"J Sui","year":"2009","unstructured":"Sui J, Hwang WC, Perez S et al (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265\u2013273. https:\/\/doi.org\/10.1038\/nsmb.1566","journal-title":"Nat Struct Mol Biol"},{"key":"5611_CR152","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41586-021-04356-8","volume":"602","author":"JJ Guthmiller","year":"2022","unstructured":"Guthmiller JJ, Han J, Utset HA et al (2022) Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature 602:314\u2013320. https:\/\/doi.org\/10.1038\/s41586-021-04356-8","journal-title":"Nature"},{"key":"5611_CR153","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","volume":"333","author":"D Corti","year":"2011","unstructured":"Corti D, Voss J, Gamblin SJ et al (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850\u2013856. https:\/\/doi.org\/10.1126\/science.1205669","journal-title":"Science"},{"key":"5611_CR154","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cell.2016.06.043","volume":"166","author":"MG Joyce","year":"2016","unstructured":"Joyce MG, Wheatley AK, Thomas PV et al (2016) Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166:609\u2013623. https:\/\/doi.org\/10.1016\/j.cell.2016.06.043","journal-title":"Cell"},{"key":"5611_CR155","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","volume":"21","author":"G Pantaleo","year":"2022","unstructured":"Pantaleo G, Correia B, Fenwick C et al (2022) Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov 21:676\u2013696. https:\/\/doi.org\/10.1038\/s41573-022-00495-3","journal-title":"Nat Rev Drug Discov"},{"key":"5611_CR156","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coviro.2017.03.002","volume":"24","author":"D Corti","year":"2017","unstructured":"Corti D, Cameroni E, Guarino B et al (2017) Tackling influenza with broadly neutralizing antibodies. Curr Opin Virol 24:60\u201369. https:\/\/doi.org\/10.1016\/j.coviro.2017.03.002","journal-title":"Curr Opin Virol"},{"key":"5611_CR157","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1084\/jem.20181624","volume":"216","author":"I Kosik","year":"2019","unstructured":"Kosik I, Angeletti D, Gibbs JS et al (2019) Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies. J Exp Med 216:304\u2013316. https:\/\/doi.org\/10.1084\/jem.20181624","journal-title":"J Exp Med"},{"key":"5611_CR158","doi-asserted-by":"publisher","first-page":"8808","DOI":"10.1128\/JVI.71.11.8808-8820.1997","volume":"71","author":"LR Hoffman","year":"1997","unstructured":"Hoffman LR, Kuntz ID, White JM (1997) Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J Virol 71:8808\u20138820. https:\/\/doi.org\/10.1128\/JVI.71.11.8808-8820.1997","journal-title":"J Virol"},{"key":"5611_CR159","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1021\/acsinfecdis.6b00194","volume":"3","author":"A Basu","year":"2017","unstructured":"Basu A, Komazin-Meredith G, McCarthy C et al (2017) Molecular mechanism underlying the action of influenza A virus fusion inhibitor MBX2546. ACS Infect Dis 3:330\u2013335. https:\/\/doi.org\/10.1021\/acsinfecdis.6b00194","journal-title":"ACS Infect Dis"},{"key":"5611_CR160","doi-asserted-by":"publisher","first-page":"104782","DOI":"10.1016\/j.antiviral.2020.104782","volume":"177","author":"AFA Hussein","year":"2020","unstructured":"Hussein AFA, Cheng H, Tundup S et al (2020) Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus. Antiviral Res 177:104782. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104782","journal-title":"Antiviral Res"},{"key":"5611_CR161","doi-asserted-by":"publisher","first-page":"eaar6221","DOI":"10.1126\/science.aar6221","volume":"363","author":"MJP van Dongen","year":"2019","unstructured":"van Dongen MJP, Kadam RU, Juraszek J et al (2019) A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science 363:eaar6221. https:\/\/doi.org\/10.1126\/science.aar6221","journal-title":"Science"},{"key":"5611_CR162","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1021\/acs.jmedchem.9b01900","volume":"63","author":"IN Gaisina","year":"2020","unstructured":"Gaisina IN, Peet NP, Cheng H et al (2020) Optimization of 4-aminopiperidines as inhibitors of influenza A Viral entry that are synergistic with oseltamivir. J Med Chem 63:3120\u20133130. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01900","journal-title":"J Med Chem"},{"key":"5611_CR163","doi-asserted-by":"publisher","first-page":"eadk9004","DOI":"10.1126\/sciadv.adk9004","volume":"10","author":"I Gaisina","year":"2024","unstructured":"Gaisina I, Li P, Du R et al (2024) An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil. Sci Adv 10:eadk9004. https:\/\/doi.org\/10.1126\/sciadv.adk9004","journal-title":"Sci Adv"},{"key":"5611_CR164","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1099\/vir.0.038679-0","volume":"93","author":"MQ Nicol","year":"2012","unstructured":"Nicol MQ, Ligertwood Y, Bacon MN et al (2012) A novel family of peptides with potent activity against influenza A viruses. J Gen Virol 93:980\u2013986. https:\/\/doi.org\/10.1099\/vir.0.038679-0","journal-title":"J Gen Virol"},{"key":"5611_CR165","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.antiviral.2014.01.015","volume":"104","author":"J Hoffmann","year":"2014","unstructured":"Hoffmann J, Schneider C, Heinbockel L et al (2014) A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment. Antiviral Res 104:23\u201333. https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.015","journal-title":"Antiviral Res"},{"key":"5611_CR166","doi-asserted-by":"publisher","first-page":"e0138426","DOI":"10.1371\/journal.pone.0138426","volume":"10","author":"W Wu","year":"2015","unstructured":"Wu W, Lin D, Shen X et al (2015) New influenza A virus entry inhibitors derived from the viral fusion peptides. PLoS ONE 10:e0138426. https:\/\/doi.org\/10.1371\/journal.pone.0138426","journal-title":"PLoS ONE"},{"key":"5611_CR167","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/med.21289","volume":"34","author":"E Vanderlinden","year":"2014","unstructured":"Vanderlinden E, Naesens L (2014) Emerging antiviral strategies to interfere with influenza virus entry. Med Res Rev 34:301\u2013339. https:\/\/doi.org\/10.1002\/med.21289","journal-title":"Med Res Rev"},{"key":"5611_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/095632020701800101","volume":"18","author":"J Balzarini","year":"2007","unstructured":"Balzarini J (2007) Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? Antivir Chem Chemother 18:1\u201311. https:\/\/doi.org\/10.1177\/095632020701800101","journal-title":"Antivir Chem Chemother"},{"key":"5611_CR169","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1128\/AAC.47.8.2518-2525.2003","volume":"47","author":"BR O\u2019Keefe","year":"2003","unstructured":"O\u2019Keefe BR, Smee DF, Turpin JA et al (2003) Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 47:2518\u20132525. https:\/\/doi.org\/10.1128\/AAC.47.8.2518-2525.2003","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR170","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.virusres.2013.12.032","volume":"181","author":"MLB Hillaire","year":"2014","unstructured":"Hillaire MLB, van Eijk M, Vogelzang-van Trierum SE et al (2014) Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo. Virus Res 181:22\u201326. https:\/\/doi.org\/10.1016\/j.virusres.2013.12.032","journal-title":"Virus Res"},{"key":"5611_CR171","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.virusres.2014.08.019","volume":"195","author":"MLB Hillaire","year":"2015","unstructured":"Hillaire MLB, van Eijk M, Vogelzang-van Trierum SE et al (2015) Assessment of the antiviral properties of recombinant surfactant protein D against influenza B virus in vitro. Virus Res 195:43\u201346. https:\/\/doi.org\/10.1016\/j.virusres.2014.08.019","journal-title":"Virus Res"},{"key":"5611_CR172","doi-asserted-by":"publisher","first-page":"108016","DOI":"10.1016\/j.celrep.2020.108016","volume":"32","author":"Y-M Liu","year":"2020","unstructured":"Liu Y-M, Shahed-Al-Mahmud M, Chen X et al (2020) A carbohydrate-binding protein from the edible lablab beans effectively blocks the infections of influenza viruses and SARS-CoV-2. Cell Rep 32:108016. https:\/\/doi.org\/10.1016\/j.celrep.2020.108016","journal-title":"Cell Rep"},{"key":"5611_CR173","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.celrep.2019.10.064","volume":"29","author":"GP Larson","year":"2019","unstructured":"Larson GP, Tran V, Y\u00fa S et al (2019) EPS8 facilitates uncoating of Influenza A virus. Cell Rep 29:2175-2183.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.064","journal-title":"Cell Rep"},{"key":"5611_CR174","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.chom.2018.04.015","volume":"23","author":"Y Fujioka","year":"2018","unstructured":"Fujioka Y, Nishide S, Ose T et al (2018) A sialylated voltage-dependent Ca2+ channel binds hemagglutinin and mediates influenza a virus entry into mammalian cells. Cell Host Microbe 23:809-818.e5. https:\/\/doi.org\/10.1016\/j.chom.2018.04.015","journal-title":"Cell Host Microbe"},{"key":"5611_CR175","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/jvi.77.1.460-469.2003","volume":"77","author":"SB Sieczkarski","year":"2003","unstructured":"Sieczkarski SB, Brown HA, Whittaker GR (2003) Role of protein kinase C betaII in influenza virus entry via late endosomes. J Virol 77:460\u2013469. https:\/\/doi.org\/10.1128\/jvi.77.1.460-469.2003","journal-title":"J Virol"},{"key":"5611_CR176","doi-asserted-by":"publisher","first-page":"e1001099","DOI":"10.1371\/journal.ppat.1001099","volume":"6","author":"T Eierhoff","year":"2010","unstructured":"Eierhoff T, Hrincius ER, Rescher U et al (2010) The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog 6:e1001099. https:\/\/doi.org\/10.1371\/journal.ppat.1001099","journal-title":"PLoS Pathog"},{"key":"5611_CR177","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1021\/acsinfecdis.9b00230","volume":"5","author":"R O\u2019Hanlon","year":"2019","unstructured":"O\u2019Hanlon R, Leyva-Grado VH, Sourisseau M et al (2019) An influenza virus entry inhibitor targets class II PI3 kinase and synergizes with oseltamivir. ACS Infect Dis 5:1779\u20131793. https:\/\/doi.org\/10.1021\/acsinfecdis.9b00230","journal-title":"ACS Infect Dis"},{"key":"5611_CR178","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-981-16-8702-0_8","volume-title":"Virus entry inhibitors: stopping the enemy at the gate","author":"J Yang","year":"2022","unstructured":"Yang J, Liu S (2022) Influenza virus entry inhibitors. In: Jiang S, Lu L (eds) Virus entry inhibitors: stopping the enemy at the gate. Springer, Singapore, pp 123\u2013135"},{"key":"5611_CR179","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ejcb.2015.05.013","volume":"94","author":"W Garten","year":"2015","unstructured":"Garten W, Braden C, Arendt A et al (2015) Influenza virus activating host proteases: identification, localization and inhibitors as potential therapeutics. Eur J Cell Biol 94:375\u2013383. https:\/\/doi.org\/10.1016\/j.ejcb.2015.05.013","journal-title":"Eur J Cell Biol"},{"key":"5611_CR180","doi-asserted-by":"publisher","first-page":"28403","DOI":"10.1074\/jbc.R110.129809","volume":"285","author":"SJ Gamblin","year":"2010","unstructured":"Gamblin SJ, Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403\u201328409. https:\/\/doi.org\/10.1074\/jbc.R110.129809","journal-title":"J Biol Chem"},{"key":"5611_CR181","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1042\/BJ20130101","volume":"452","author":"D Meyer","year":"2013","unstructured":"Meyer D, Sielaff F, Hammami M et al (2013) Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem J 452:331\u2013343. https:\/\/doi.org\/10.1042\/BJ20130101","journal-title":"Biochem J"},{"key":"5611_CR182","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1021\/jm051272l","volume":"49","author":"T Steinmetzer","year":"2006","unstructured":"Steinmetzer T, Schweinitz A, St\u00fcrzebecher A et al (2006) Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 49:4116\u20134126. https:\/\/doi.org\/10.1021\/jm051272l","journal-title":"J Med Chem"},{"key":"5611_CR183","doi-asserted-by":"publisher","first-page":"21992","DOI":"10.1074\/jbc.M111.332643","volume":"287","author":"GL Becker","year":"2012","unstructured":"Becker GL, Lu Y, Hardes K et al (2012) Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 287:21992\u201322003. https:\/\/doi.org\/10.1074\/jbc.M111.332643","journal-title":"J Biol Chem"},{"key":"5611_CR184","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1016\/j.vaccine.2012.10.001","volume":"30","author":"E B\u00f6ttcher-Friebertsh\u00e4user","year":"2012","unstructured":"B\u00f6ttcher-Friebertsh\u00e4user E, Lu Y, Meyer D et al (2012) Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. Vaccine 30:7374\u20137380. https:\/\/doi.org\/10.1016\/j.vaccine.2012.10.001","journal-title":"Vaccine"},{"issue":"Pt 1","key":"5611_CR185","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1099\/0022-1317-65-1-191","volume":"65","author":"OP Zhirnov","year":"1984","unstructured":"Zhirnov OP, Ovcharenko AV, Bukrinskaya AG (1984) Suppression of influenza virus replication in infected mice by protease inhibitors. J Gen Virol 65(Pt 1):191\u2013196. https:\/\/doi.org\/10.1099\/0022-1317-65-1-191","journal-title":"J Gen Virol"},{"key":"5611_CR186","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3851\/IMP1715","volume":"21","author":"OP Zhirnov","year":"2011","unstructured":"Zhirnov OP, Matrosovich TY, Matrosovich MN, Klenk H-D (2011) Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir Chem Chemother 21:169\u2013174. https:\/\/doi.org\/10.3851\/IMP1715","journal-title":"Antivir Chem Chemother"},{"key":"5611_CR187","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.antiviral.2011.07.014","volume":"92","author":"OP Zhirnov","year":"2011","unstructured":"Zhirnov OP, Klenk HD, Wright PF (2011) Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res 92:27\u201336. https:\/\/doi.org\/10.1016\/j.antiviral.2011.07.014","journal-title":"Antiviral Res"},{"key":"5611_CR188","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bbrc.2010.09.020","volume":"401","author":"S-Q Wang","year":"2010","unstructured":"Wang S-Q, Cheng X-C, Dong W-L et al (2010) Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus. Biochem Biophys Res Commun 401:188\u2013191. https:\/\/doi.org\/10.1016\/j.bbrc.2010.09.020","journal-title":"Biochem Biophys Res Commun"},{"key":"5611_CR189","doi-asserted-by":"publisher","first-page":"8445","DOI":"10.1021\/jm500892k","volume":"57","author":"Y Xie","year":"2014","unstructured":"Xie Y, Xu D, Huang B et al (2014) Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase. J Med Chem 57:8445\u20138458. https:\/\/doi.org\/10.1021\/jm500892k","journal-title":"J Med Chem"},{"key":"5611_CR190","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/cbdd.13060","volume":"91","author":"X Lin","year":"2018","unstructured":"Lin X, Qin-Hua C, Peng L et al (2018) The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors. Chem Biol Drug Des 91:105\u2013115. https:\/\/doi.org\/10.1111\/cbdd.13060","journal-title":"Chem Biol Drug Des"},{"key":"5611_CR191","doi-asserted-by":"publisher","first-page":"9976","DOI":"10.1021\/acs.jmedchem.8b01065","volume":"61","author":"J Zhang","year":"2018","unstructured":"Zhang J, Murugan NA, Tian Y et al (2018) Structure-based optimization of N-substituted oseltamivir derivatives as potent anti-Influenza A Virus agents with significantly improved potency against oseltamivir-resistant N1\u2013H274Y Variant. J Med Chem 61:9976\u20139999. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01065","journal-title":"J Med Chem"},{"key":"5611_CR192","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1021\/acs.jmedchem.8b00929","volume":"61","author":"J Zhang","year":"2018","unstructured":"Zhang J, Poongavanam V, Kang D et al (2018) Optimization of N-substituted oseltamivir derivatives as potent inhibitors of group-1 and -2 influenza A neuraminidases, including a drug-resistant variant. J Med Chem 61:6379\u20136397. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00929","journal-title":"J Med Chem"},{"key":"5611_CR193","doi-asserted-by":"publisher","first-page":"113097","DOI":"10.1016\/j.ejmech.2020.113097","volume":"212","author":"R Jia","year":"2021","unstructured":"Jia R, Zhang J, Bertagnin C et al (2021) Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity. Eur J Med Chem 212:113097. https:\/\/doi.org\/10.1016\/j.ejmech.2020.113097","journal-title":"Eur J Med Chem"},{"key":"5611_CR194","doi-asserted-by":"publisher","first-page":"17992","DOI":"10.1021\/acs.jmedchem.1c01366","volume":"64","author":"H Ju","year":"2021","unstructured":"Ju H, Murugan NA, Hou L et al (2021) Identification of C5-NH2 modified oseltamivir derivatives as novel influenza neuraminidase inhibitors with highly improved antiviral activities and favorable druggability. J Med Chem 64:17992\u201318009. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01366","journal-title":"J Med Chem"},{"key":"5611_CR195","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.3390\/molecules27196426","volume":"27","author":"R Jia","year":"2022","unstructured":"Jia R, Zhang J, Zhang J et al (2022) Discovery of novel boron-containing N-substituted oseltamivir derivatives as anti-Influenza a virus agents for overcoming N1\u2013H274Y oseltamivir-resistant. Molecules 27:6426. https:\/\/doi.org\/10.3390\/molecules27196426","journal-title":"Molecules"},{"key":"5611_CR196","doi-asserted-by":"publisher","first-page":"11550","DOI":"10.1021\/acs.jmedchem.1c01970","volume":"65","author":"H Ju","year":"2022","unstructured":"Ju H, Hou L, Zhao F et al (2022) Iterative optimization and structure-activity relationship studies of oseltamivir amino derivatives as potent and selective neuraminidase inhibitors via targeting 150-cavity. J Med Chem 65:11550\u201311573. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01970","journal-title":"J Med Chem"},{"key":"5611_CR197","doi-asserted-by":"publisher","first-page":"115275","DOI":"10.1016\/j.ejmech.2023.115275","volume":"252","author":"R Jia","year":"2023","unstructured":"Jia R, Zhang J, Shi F et al (2023) Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties. Eur J Med Chem 252:115275. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115275","journal-title":"Eur J Med Chem"},{"key":"5611_CR198","doi-asserted-by":"publisher","first-page":"2277135","DOI":"10.1080\/14756366.2023.2277135","volume":"38","author":"J Zhang","year":"2023","unstructured":"Zhang J, Liu C, Jia R et al (2023) A novel N-heterocycles substituted oseltamivir derivatives as potent inhibitors of influenza virus neuraminidase: discovery, synthesis and biological evaluation. J Enzyme Inhib Med Chem 38:2277135. https:\/\/doi.org\/10.1080\/14756366.2023.2277135","journal-title":"J Enzyme Inhib Med Chem"},{"key":"5611_CR199","doi-asserted-by":"publisher","first-page":"22191","DOI":"10.1021\/acs.jmedchem.4c02222","volume":"67","author":"J Zhang","year":"2024","unstructured":"Zhang J, Jia R, Jia H et al (2024) Elaborate structural modifications yielding novel boron-containing n-substituted oseltamivir derivatives as potent neuraminidase inhibitors with significantly improved broad-spectrum antiresistance profiles. J Med Chem 67:22191\u201322217. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02222","journal-title":"J Med Chem"},{"key":"5611_CR200","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1021\/jm040891b","volume":"48","author":"SJF Macdonald","year":"2005","unstructured":"Macdonald SJF, Cameron R, Demaine DA et al (2005) Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem 48:2964\u20132971. https:\/\/doi.org\/10.1021\/jm040891b","journal-title":"J Med Chem"},{"key":"5611_CR201","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.bmcl.2003.09.102","volume":"14","author":"KG Watson","year":"2004","unstructured":"Watson KG, Cameron R, Fenton RJ et al (2004) Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorg Med Chem Lett 14:1589\u20131592. https:\/\/doi.org\/10.1016\/j.bmcl.2003.09.102","journal-title":"Bioorg Med Chem Lett"},{"key":"5611_CR202","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1128\/AAC.45.3.743-748.2001","volume":"45","author":"DF Smee","year":"2001","unstructured":"Smee DF, Huffman JH, Morrison AC et al (2001) Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45:743\u2013748. https:\/\/doi.org\/10.1128\/AAC.45.3.743-748.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR203","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1128\/AAC.45.3.749-757.2001","volume":"45","author":"RW Sidwell","year":"2001","unstructured":"Sidwell RW, Smee DF, Huffman JH et al (2001) In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 45:749\u2013757. https:\/\/doi.org\/10.1128\/AAC.45.3.749-757.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR204","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1021\/jm000468c","volume":"44","author":"GT Wang","year":"2001","unstructured":"Wang GT, Chen Y, Wang S et al (2001) Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. J Med Chem 44:1192\u20131201. https:\/\/doi.org\/10.1021\/jm000468c","journal-title":"J Med Chem"},{"key":"5611_CR205","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1128\/AAC.46.4.1014-1021.2002","volume":"46","author":"WM Kati","year":"2002","unstructured":"Kati WM, Montgomery D, Carrick R et al (2002) In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother 46:1014\u20131021. https:\/\/doi.org\/10.1128\/AAC.46.4.1014-1021.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR206","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1126\/science.1232552","volume":"340","author":"J-H Kim","year":"2013","unstructured":"Kim J-H, Resende R, Wennekes T et al (2013) Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. Science 340:71\u201375. https:\/\/doi.org\/10.1126\/science.1232552","journal-title":"Science"},{"key":"5611_CR207","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/md16100377","volume":"16","author":"J Li","year":"2018","unstructured":"Li J, Chen Y, Yuan N et al (2018) A novel natural influenza A H1N1 virus neuraminidase inhibitory peptide derived from cod skin hydrolysates and its antiviral mechanism. Mar Drugs 16:377. https:\/\/doi.org\/10.3390\/md16100377","journal-title":"Mar Drugs"},{"key":"5611_CR208","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1039\/c9md00473d","volume":"11","author":"J Chen","year":"2020","unstructured":"Chen J, Feng S, Xu Y et al (2020) Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase. RSC Med Chem 11:148\u2013154. https:\/\/doi.org\/10.1039\/c9md00473d","journal-title":"RSC Med Chem"},{"key":"5611_CR209","doi-asserted-by":"publisher","first-page":"611121","DOI":"10.3389\/fcell.2020.611121","volume":"8","author":"C Albrecht","year":"2020","unstructured":"Albrecht C, Kuznetsov AS, Appert-Collin A et al (2020) Transmembrane peptides as a new strategy to inhibit neuraminidase-1 activation. Front Cell Dev Biol 8:611121. https:\/\/doi.org\/10.3389\/fcell.2020.611121","journal-title":"Front Cell Dev Biol"},{"key":"5611_CR210","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"Y-Q Chen","year":"2018","unstructured":"Chen Y-Q, Wohlbold TJ, Zheng N-Y et al (2018) Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173:417-429.e10. https:\/\/doi.org\/10.1016\/j.cell.2018.03.030","journal-title":"Cell"},{"key":"5611_CR211","doi-asserted-by":"publisher","first-page":"00417","DOI":"10.1128\/mBio.00417-16","volume":"7","author":"MJ Memoli","year":"2016","unstructured":"Memoli MJ, Shaw PA, Han A et al (2016) Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model. MBio 7:00417\u201301416. https:\/\/doi.org\/10.1128\/mBio.00417-16","journal-title":"MBio"},{"key":"5611_CR212","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1093\/cid\/ciz639","volume":"70","author":"HE Maier","year":"2020","unstructured":"Maier HE, Nachbagauer R, Kuan G et al (2020) Pre-existing antineuraminidase antibodies are associated with shortened duration of influenza A(H1N1)pdm virus shedding and illness in naturally infected adults. Clin Infect Dis 70:2290\u20132297. https:\/\/doi.org\/10.1093\/cid\/ciz639","journal-title":"Clin Infect Dis"},{"key":"5611_CR213","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis935","volume":"207","author":"RB Couch","year":"2013","unstructured":"Couch RB, Atmar RL, Franco LM et al (2013) Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 207:974\u2013981. https:\/\/doi.org\/10.1093\/infdis\/jis935","journal-title":"J Infect Dis"},{"key":"5611_CR214","doi-asserted-by":"publisher","first-page":"02332","DOI":"10.1128\/mBio.02332-17","volume":"9","author":"F Krammer","year":"2018","unstructured":"Krammer F, Fouchier RAM, Eichelberger MC et al (2018) NAction! how can neuraminidase-based immunity contribute to better influenza virus vaccines? MBio 9:02332\u201302417. https:\/\/doi.org\/10.1128\/mBio.02332-17","journal-title":"MBio"},{"key":"5611_CR215","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo DJ, Palese P, Wilson PC, Ravetch JV (2016) Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126:605\u2013610. https:\/\/doi.org\/10.1172\/JCI84428","journal-title":"J Clin Invest"},{"key":"5611_CR216","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer D, Zhu X, McMahon M et al (2019) Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366:499\u2013504. https:\/\/doi.org\/10.1126\/science.aay0678","journal-title":"Science"},{"key":"5611_CR217","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1038\/s41467-022-34521-0","volume":"13","author":"A Yasuhara","year":"2022","unstructured":"Yasuhara A, Yamayoshi S, Kiso M et al (2022) A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nat Commun 13:6602. https:\/\/doi.org\/10.1038\/s41467-022-34521-0","journal-title":"Nat Commun"},{"key":"5611_CR218","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.immuni.2020.08.015","volume":"53","author":"A Madsen","year":"2020","unstructured":"Madsen A, Dai Y-N, McMahon M et al (2020) Human antibodies targeting influenza B virus neuraminidase active site are broadly protective. Immunity 53:852-863.e7. https:\/\/doi.org\/10.1016\/j.immuni.2020.08.015","journal-title":"Immunity"},{"key":"5611_CR219","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-023-06136-y","volume":"618","author":"C Momont","year":"2023","unstructured":"Momont C, Dang HV, Zatta F et al (2023) A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. Nature 618:590\u2013597. https:\/\/doi.org\/10.1038\/s41586-023-06136-y","journal-title":"Nature"},{"key":"5611_CR220","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2174\/1568026617666170224122508","volume":"17","author":"Y Hu","year":"2017","unstructured":"Hu Y, Sneyd H, Dekant R, Wang J (2017) Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target. Curr Top Med Chem 17:2271\u20132285. https:\/\/doi.org\/10.2174\/1568026617666170224122508","journal-title":"Curr Top Med Chem"},{"key":"5611_CR221","doi-asserted-by":"publisher","first-page":"e1005062","DOI":"10.1371\/journal.ppat.1005062","volume":"11","author":"M Kakisaka","year":"2015","unstructured":"Kakisaka M, Sasaki Y, Yamada K et al (2015) A novel antiviral target structure involved in the RNA binding, dimerization, and nuclear export functions of the Influenza A virus nucleoprotein. PLoS Pathog 11:e1005062. https:\/\/doi.org\/10.1371\/journal.ppat.1005062","journal-title":"PLoS Pathog"},{"key":"5611_CR222","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbrc.2010.03.058","volume":"394","author":"K Hagiwara","year":"2010","unstructured":"Hagiwara K, Kondoh Y, Ueda A et al (2010) Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Biochem Biophys Res Commun 394:721\u2013727. https:\/\/doi.org\/10.1016\/j.bbrc.2010.03.058","journal-title":"Biochem Biophys Res Commun"},{"key":"5611_CR223","doi-asserted-by":"publisher","first-page":"19151","DOI":"10.1073\/pnas.1013592107","volume":"107","author":"C-Y Su","year":"2010","unstructured":"Su C-Y, Cheng T-JR, Lin M-I et al (2010) High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci U S A 107:19151\u201319156. https:\/\/doi.org\/10.1073\/pnas.1013592107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR224","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1021\/acsinfecdis.7b00120","volume":"4","author":"KM White","year":"2018","unstructured":"White KM, Abreu PJr, Wang H, et al (2018) Broad spectrum inhibitor of influenza A and B viruses targeting the viral nucleoprotein. ACS Infect Dis 4:146\u2013157. https:\/\/doi.org\/10.1021\/acsinfecdis.7b00120","journal-title":"ACS Infect Dis"},{"key":"5611_CR225","doi-asserted-by":"publisher","first-page":"e0277073","DOI":"10.1371\/journal.pone.0277073","volume":"18","author":"E Correa-Padilla","year":"2023","unstructured":"Correa-Padilla E, Hern\u00e1ndez-Cano A, Cuevas G et al (2023) Modifications in the piperazine ring of nucleozin affect anti-influenza activity. PLoS ONE 18:e0277073. https:\/\/doi.org\/10.1371\/journal.pone.0277073","journal-title":"PLoS ONE"},{"key":"5611_CR226","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/nbt.1638","volume":"28","author":"RY Kao","year":"2010","unstructured":"Kao RY, Yang D, Lau L-S et al (2010) Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28:600\u2013605. https:\/\/doi.org\/10.1038\/nbt.1638","journal-title":"Nat Biotechnol"},{"key":"5611_CR227","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.antiviral.2016.07.024","volume":"134","author":"Y Jang","year":"2016","unstructured":"Jang Y, Lee HW, Shin JS et al (2016) Antiviral activity of KR-23502 targeting nuclear export of influenza B virus ribonucleoproteins. Antiviral Res 134:77\u201388. https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.024","journal-title":"Antiviral Res"},{"key":"5611_CR228","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1111\/jcmm.13467","volume":"22","author":"F Huang","year":"2018","unstructured":"Huang F, Chen J, Zhang J et al (2018) Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein. J Cell Mol Med 22:1826\u20131839. https:\/\/doi.org\/10.1111\/jcmm.13467","journal-title":"J Cell Mol Med"},{"key":"5611_CR229","doi-asserted-by":"publisher","first-page":"e01432","DOI":"10.1128\/JVI.01432-20","volume":"95","author":"F Yang","year":"2021","unstructured":"Yang F, Pang B, Lai KK et al (2021) Discovery of a novel specific inhibitor targeting influenza a virus nucleoprotein with pleiotropic inhibitory effects on various steps of the viral life cycle. J Virol 95:e01432-e1520. https:\/\/doi.org\/10.1128\/JVI.01432-20","journal-title":"J Virol"},{"key":"5611_CR230","doi-asserted-by":"publisher","first-page":"14465","DOI":"10.1021\/acs.jmedchem.1c00979","volume":"64","author":"L Tang","year":"2021","unstructured":"Tang L, Yan H, Wu W et al (2021) Synthesis and anti-influenza virus effects of novel substituted polycyclic pyridone derivatives modified from Baloxavir. J Med Chem 64:14465\u201314476. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00979","journal-title":"J Med Chem"},{"key":"5611_CR231","doi-asserted-by":"publisher","first-page":"9403","DOI":"10.1021\/acs.jmedchem.0c00565","volume":"63","author":"AA Ivashchenko","year":"2020","unstructured":"Ivashchenko AA, Mitkin OD, Jones JC et al (2020) Non-rigid diarylmethyl analogs of baloxavir as cap-dependent endonuclease inhibitors of Influenza viruses. J Med Chem 63:9403\u20139420. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00565","journal-title":"J Med Chem"},{"key":"5611_CR232","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/jac\/dkaa524","volume":"76","author":"AA Ivashchenko","year":"2021","unstructured":"Ivashchenko AA, Mitkin OD, Jones JC et al (2021) Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir. J Antimicrob Chemother 76:1010\u20131018. https:\/\/doi.org\/10.1093\/jac\/dkaa524","journal-title":"J Antimicrob Chemother"},{"key":"5611_CR233","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1128\/AAC.40.5.1189","volume":"40","author":"JE Tomassini","year":"1996","unstructured":"Tomassini JE, Davies ME, Hastings JC et al (1996) A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother 40:1189\u20131193. https:\/\/doi.org\/10.1128\/AAC.40.5.1189","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR234","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1021\/jm020334u","volume":"46","author":"KEB Parkes","year":"2003","unstructured":"Parkes KEB, Ermert P, F\u00e4ssler J et al (2003) Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 46:1153\u20131164. https:\/\/doi.org\/10.1021\/jm020334u","journal-title":"J Med Chem"},{"key":"5611_CR235","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1128\/AAC.38.12.2827","volume":"38","author":"J Tomassini","year":"1994","unstructured":"Tomassini J, Selnick H, Davies ME et al (1994) Inhibition of cap (m7G pppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 38:2827\u20132837. https:\/\/doi.org\/10.1128\/AAC.38.12.2827","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR236","doi-asserted-by":"publisher","first-page":"e1002831","DOI":"10.1371\/journal.ppat.1002831","volume":"8","author":"E Kowalinski","year":"2012","unstructured":"Kowalinski E, Zubieta C, Wolkerstorfer A et al (2012) Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase. PLoS Pathog 8:e1002831. https:\/\/doi.org\/10.1371\/journal.ppat.1002831","journal-title":"PLoS Pathog"},{"key":"5611_CR237","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1021\/cb200439z","volume":"7","author":"BM Baughman","year":"2012","unstructured":"Baughman BM, Jake Slavish P, DuBois RM et al (2012) Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. ACS Chem Biol 7:526\u2013534. https:\/\/doi.org\/10.1021\/cb200439z","journal-title":"ACS Chem Biol"},{"key":"5611_CR238","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1021\/ml4001112","volume":"4","author":"HY Sagong","year":"2013","unstructured":"Sagong HY, Parhi A, Bauman JD et al (2013) 3-Hydroxyquinolin-2(1H)-ones as inhibitors of Influenza A endonuclease. ACS Med Chem Lett 4:547\u2013550. https:\/\/doi.org\/10.1021\/ml4001112","journal-title":"ACS Med Chem Lett"},{"key":"5611_CR239","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/cmdc.201900084","volume":"14","author":"HY Sagong","year":"2019","unstructured":"Sagong HY, Bauman JD, Nogales A et al (2019) Aryl and arylalkyl substituted 3-hydroxypyridin-2(1H)-ones: synthesis and evaluation as inhibitors of Influenza A endonuclease. ChemMedChem 14:1204\u20131223. https:\/\/doi.org\/10.1002\/cmdc.201900084","journal-title":"ChemMedChem"},{"key":"5611_CR240","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/cb400400j","volume":"8","author":"JD Bauman","year":"2013","unstructured":"Bauman JD, Patel D, Baker SF et al (2013) Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors. ACS Chem Biol 8:2501\u20132508. https:\/\/doi.org\/10.1021\/cb400400j","journal-title":"ACS Chem Biol"},{"key":"5611_CR241","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.1016\/j.bmc.2013.08.053","volume":"21","author":"AK Parhi","year":"2013","unstructured":"Parhi AK, Xiang A, Bauman JD et al (2013) Phenyl substituted 3-hydroxypyridin-2(1H)-ones: inhibitors of influenza A endonuclease. Bioorg Med Chem 21:6435\u20136446. https:\/\/doi.org\/10.1016\/j.bmc.2013.08.053","journal-title":"Bioorg Med Chem"},{"key":"5611_CR242","doi-asserted-by":"publisher","first-page":"112048","DOI":"10.1016\/j.ejmech.2020.112048","volume":"189","author":"Y Liao","year":"2020","unstructured":"Liao Y, Ye Y, Li S et al (2020) Synthesis and SARs of dopamine derivatives as potential inhibitors of influenza virus PAN endonuclease. Eur J Med Chem 189:112048. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112048","journal-title":"Eur J Med Chem"},{"key":"5611_CR243","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1016\/j.bmc.2018.07.046","volume":"26","author":"S Ferro","year":"2018","unstructured":"Ferro S, Gitto R, Buemi MR et al (2018) Identification of influenza PA-Nter endonuclease inhibitors using pharmacophore- and docking-based virtual screening. Bioorg Med Chem 26:4544\u20134550. https:\/\/doi.org\/10.1016\/j.bmc.2018.07.046","journal-title":"Bioorg Med Chem"},{"key":"5611_CR244","doi-asserted-by":"publisher","first-page":"e19825","DOI":"10.1371\/journal.pone.0019825","volume":"6","author":"Y Iwai","year":"2011","unstructured":"Iwai Y, Murakami K, Gomi Y et al (2011) Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. PLoS ONE 6:e19825. https:\/\/doi.org\/10.1371\/journal.pone.0019825","journal-title":"PLoS ONE"},{"key":"5611_CR245","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.bmcl.2015.03.013","volume":"25","author":"MJ Boyd","year":"2015","unstructured":"Boyd MJ, Bandarage UK, Bennett H et al (2015) Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. Bioorg Med Chem Lett 25:1990\u20131994. https:\/\/doi.org\/10.1016\/j.bmcl.2015.03.013","journal-title":"Bioorg Med Chem Lett"},{"key":"5611_CR246","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3390\/molecules28041849","volume":"28","author":"X Li","year":"2023","unstructured":"Li X, Xu Y, Li W et al (2023) Design, synthesis, biological evaluation, and molecular dynamics simulation of influenza polymerase PB2 inhibitors. Molecules 28:1849. https:\/\/doi.org\/10.3390\/molecules28041849","journal-title":"Molecules"},{"key":"5611_CR247","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1021\/acsmedchemlett.6b00486","volume":"8","author":"LJ Farmer","year":"2017","unstructured":"Farmer LJ, Clark MP, Boyd MJ et al (2017) Discovery of novel, orally bioavailable \u03b2-amino acid Azaindole inhibitors of influenza PB2. ACS Med Chem Lett 8:256\u2013260. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00486","journal-title":"ACS Med Chem Lett"},{"key":"5611_CR248","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1089\/adt.2015.668","volume":"13","author":"F-F Roch","year":"2015","unstructured":"Roch F-F, Hinterk\u00f6rner G, Menke J et al (2015) An RNA hybridization assay for screening Influenza A virus polymerase inhibitors using the entire ribonucleoprotein complex. Assay Drug Dev Technol 13:488\u2013506. https:\/\/doi.org\/10.1089\/adt.2015.668","journal-title":"Assay Drug Dev Technol"},{"key":"5611_CR249","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.micinf.2020.05.021","volume":"22","author":"Y Tian","year":"2020","unstructured":"Tian Y, Sang H, Liu M et al (2020) Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation. Microbes Infect 22:254\u2013262. https:\/\/doi.org\/10.1016\/j.micinf.2020.05.021","journal-title":"Microbes Infect"},{"key":"5611_CR250","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1093\/jac\/dkw194","volume":"71","author":"S Yuan","year":"2016","unstructured":"Yuan S, Chu H, Zhang K et al (2016) A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication. J Antimicrob Chemother 71:2489\u20132497. https:\/\/doi.org\/10.1093\/jac\/dkw194","journal-title":"J Antimicrob Chemother"},{"key":"5611_CR251","doi-asserted-by":"publisher","first-page":"e1002668","DOI":"10.1371\/journal.ppat.1002668","volume":"8","author":"MB Ortigoza","year":"2012","unstructured":"Ortigoza MB, Dibben O, Maamary J et al (2012) A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog 8:e1002668. https:\/\/doi.org\/10.1371\/journal.ppat.1002668","journal-title":"PLoS Pathog"},{"key":"5611_CR252","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1021\/acs.jmedchem.1c01257","volume":"65","author":"X Liu","year":"2022","unstructured":"Liu X, Liang J, Yu Y et al (2022) Discovery of aryl benzoyl hydrazide derivatives as novel potent broad-spectrum inhibitors of influenza A virus RNA-dependent RNA polymerase (RdRp). J Med Chem 65:3814\u20133832. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01257","journal-title":"J Med Chem"},{"key":"5611_CR253","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.tim.2013.03.006","volume":"21","author":"A Loregian","year":"2013","unstructured":"Loregian A, Pal\u00f9 G (2013) How academic labs can approach the drug discovery process as a way to synergize with big pharma. Trends Microbiol 21:261\u2013264. https:\/\/doi.org\/10.1016\/j.tim.2013.03.006","journal-title":"Trends Microbiol"},{"key":"5611_CR254","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/rmv.356","volume":"12","author":"A Loregian","year":"2002","unstructured":"Loregian A, Marsden HS, Pal\u00f9 G (2002) Protein-protein interactions as targets for antiviral chemotherapy. Rev Med Virol 12:239\u2013262. https:\/\/doi.org\/10.1002\/rmv.356","journal-title":"Rev Med Virol"},{"key":"5611_CR255","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/jcp.20356","volume":"204","author":"A Loregian","year":"2005","unstructured":"Loregian A, Pal\u00f9 G (2005) Disruption of protein-protein interactions: towards new targets for chemotherapy. J Cell Physiol 204:750\u2013762. https:\/\/doi.org\/10.1002\/jcp.20356","journal-title":"J Cell Physiol"},{"key":"5611_CR256","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.apsb.2021.11.018","volume":"12","author":"L Hou","year":"2022","unstructured":"Hou L, Zhang Y, Ju H et al (2022) Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins. Acta Pharm Sin B 12:1805\u20131824. https:\/\/doi.org\/10.1016\/j.apsb.2021.11.018","journal-title":"Acta Pharm Sin B"},{"key":"5611_CR257","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","volume":"71","author":"A Loregian","year":"2014","unstructured":"Loregian A, Mercorelli B, Nannetti G et al (2014) Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci 71:3659\u20133683. https:\/\/doi.org\/10.1007\/s00018-014-1615-2","journal-title":"Cell Mol Life Sci"},{"key":"5611_CR258","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.antiviral.2013.05.014","volume":"99","author":"G Pal\u00f9","year":"2013","unstructured":"Pal\u00f9 G, Loregian A (2013) Inhibition of herpesvirus and influenza virus replication by blocking polymerase subunit interactions. Antiviral Res 99:318\u2013327. https:\/\/doi.org\/10.1016\/j.antiviral.2013.05.014","journal-title":"Antiviral Res"},{"key":"5611_CR259","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/nature07225","volume":"454","author":"E Obayashi","year":"2008","unstructured":"Obayashi E, Yoshida H, Kawai F et al (2008) The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 454:1127\u20131131. https:\/\/doi.org\/10.1038\/nature07225","journal-title":"Nature"},{"key":"5611_CR260","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/emboj.2009.138","volume":"28","author":"K Sugiyama","year":"2009","unstructured":"Sugiyama K, Obayashi E, Kawaguchi A et al (2009) Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO J 28:1803\u20131811. https:\/\/doi.org\/10.1038\/emboj.2009.138","journal-title":"EMBO J"},{"key":"5611_CR261","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/nature07120","volume":"454","author":"X He","year":"2008","unstructured":"He X, Zhou J, Bartlam M et al (2008) Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 454:1123\u20131126. https:\/\/doi.org\/10.1038\/nature07120","journal-title":"Nature"},{"key":"5611_CR262","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1073\/pnas.1119817109","volume":"109","author":"G Muratore","year":"2012","unstructured":"Muratore G, Goracci L, Mercorelli B et al (2012) Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A 109:6247. https:\/\/doi.org\/10.1073\/pnas.1119817109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR263","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1128\/AAC.01219-12","volume":"56","author":"G Muratore","year":"2012","unstructured":"Muratore G, Mercorelli B, Goracci L et al (2012) Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses. Antimicrob Agents Chemother 56:6009\u20136013. https:\/\/doi.org\/10.1128\/AAC.01219-12","journal-title":"Antimicrob Agents Chemother"},{"key":"5611_CR264","doi-asserted-by":"publisher","first-page":"10118","DOI":"10.1021\/jm401560v","volume":"56","author":"S Massari","year":"2013","unstructured":"Massari S, Nannetti G, Goracci L et al (2013) Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly. J Med Chem 56:10118\u201310131. https:\/\/doi.org\/10.1021\/jm401560v","journal-title":"J Med Chem"},{"key":"5611_CR265","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.1016\/j.bmcl.2013.08.048","volume":"23","author":"U Kessler","year":"2013","unstructured":"Kessler U, Castagnolo D, Pagano M et al (2013) Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus. Bioorg Med Chem Lett 23:5575\u20135577. https:\/\/doi.org\/10.1016\/j.bmcl.2013.08.048","journal-title":"Bioorg Med Chem Lett"},{"key":"5611_CR266","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1021\/jm500300r","volume":"57","author":"S Lepri","year":"2014","unstructured":"Lepri S, Nannetti G, Muratore G et al (2014) Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds. J Med Chem 57:4337\u20134350. https:\/\/doi.org\/10.1021\/jm500300r","journal-title":"J Med Chem"},{"key":"5611_CR267","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bmcl.2013.11.019","volume":"24","author":"C Tintori","year":"2014","unstructured":"Tintori C, Laurenzana I, Fallacara AL et al (2014) High-throughput docking for the identification of new influenza A virus polymerase inhibitors targeting the PA\u2013PB1 protein\u2013protein interaction. Bioorg Med Chem Lett 24:280\u2013282. https:\/\/doi.org\/10.1016\/j.bmcl.2013.11.019","journal-title":"Bioorg Med Chem Lett"},{"key":"5611_CR268","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1021\/acs.jmedchem.5b00012","volume":"58","author":"S Massari","year":"2015","unstructured":"Massari S, Nannetti G, Desantis J et al (2015) A broad anti-influenza hybrid small molecule that potently disrupts the interaction of polymerase acidic protein-basic protein 1 (PA-PB1) subunits. J Med Chem 58:3830\u20133842. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00012","journal-title":"J Med Chem"},{"key":"5611_CR269","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1021\/acs.jmedchem.5b01935","volume":"59","author":"IML Trist","year":"2016","unstructured":"Trist IML, Nannetti G, Tintori C et al (2016) 4,6-Diphenylpyridines as promising novel anti-influenza agents targeting the PA-PB1 protein\u2013protein interaction: structure-activity relationships exploration with the aid of molecular modeling. J Med Chem 59:2688\u20132703. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01935","journal-title":"J Med Chem"},{"key":"5611_CR270","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejmech.2017.06.015","volume":"138","author":"J Desantis","year":"2017","unstructured":"Desantis J, Nannetti G, Massari S et al (2017) Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. Eur J Med Chem 138:128\u2013139. https:\/\/doi.org\/10.1016\/j.ejmech.2017.06.015","journal-title":"Eur J Med Chem"},{"key":"5611_CR271","doi-asserted-by":"publisher","first-page":"7944","DOI":"10.1039\/c7ob02085f","volume":"15","author":"S Massari","year":"2017","unstructured":"Massari S, Desantis J, Nannetti G et al (2017) Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives. Org Biomol Chem 15:7944\u20137955. https:\/\/doi.org\/10.1039\/c7ob02085f","journal-title":"Org Biomol Chem"},{"key":"5611_CR272","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ejmech.2018.08.032","volume":"157","author":"I D\u2019Agostino","year":"2018","unstructured":"D\u2019Agostino I, Giacchello I, Nannetti G et al (2018) Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction. Eur J Med Chem 157:743\u2013758. https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.032","journal-title":"Eur J Med Chem"},{"key":"5611_CR273","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.antiviral.2019.03.003","volume":"165","author":"G Nannetti","year":"2019","unstructured":"Nannetti G, Massari S, Mercorelli B et al (2019) Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance. Antiviral Res 165:55\u201364. https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.003","journal-title":"Antiviral Res"},{"key":"5611_CR274","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1021\/acschembio.9b00552","volume":"15","author":"J Zhang","year":"2020","unstructured":"Zhang J, Hu Y, Wu N, Wang J (2020) Discovery of Influenza Polymerase PA-PB1 interaction inhibitors using an in vitro split-luciferase complementation-based assay. ACS Chem Biol 15:74\u201382. https:\/\/doi.org\/10.1021\/acschembio.9b00552","journal-title":"ACS Chem Biol"},{"key":"5611_CR275","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112944","volume":"209","author":"S Massari","year":"2021","unstructured":"Massari S, Bertagnin C, Pismataro MC et al (2021) Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase. Eur J Med Chem 209:112944. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112944","journal-title":"Eur J Med Chem"},{"key":"5611_CR276","doi-asserted-by":"publisher","first-page":"113494","DOI":"10.1016\/j.ejmech.2021.113494","volume":"221","author":"MC Pismataro","year":"2021","unstructured":"Pismataro MC, Felicetti T, Bertagnin C et al (2021) 1,2,4-Triazolo[1,5-a]pyrimidines: efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. Eur J Med Chem 221:113494. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113494","journal-title":"Eur J Med Chem"},{"key":"5611_CR277","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1021\/acs.jmedchem.1c01527","volume":"65","author":"S Mizuta","year":"2022","unstructured":"Mizuta S, Otaki H, Ishikawa T et al (2022) Lead optimization of Influenza Virus RNA polymerase inhibitors targeting PA-PB1 interaction. J Med Chem 65:369\u2013385. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01527","journal-title":"J Med Chem"},{"key":"5611_CR278","doi-asserted-by":"publisher","first-page":"116737","DOI":"10.1016\/j.ejmech.2024.116737","volume":"277","author":"A Bonomini","year":"2024","unstructured":"Bonomini A, Felicetti T, Pacetti M et al (2024) Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization. Eur J Med Chem 277:116737. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116737","journal-title":"Eur J Med Chem"},{"key":"5611_CR279","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3390\/pharmaceutics16070954","volume":"16","author":"I Giacchello","year":"2024","unstructured":"Giacchello I, Cianciusi A, Bertagnin C et al (2024) Exploring a new generation of pyrimidine and pyridine derivatives as anti-influenza agents targeting the polymerase PA-PB1 subunits interaction. Pharmaceutics 16:954. https:\/\/doi.org\/10.3390\/pharmaceutics16070954","journal-title":"Pharmaceutics"},{"key":"5611_CR280","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1038\/s41598-018-22875-9","volume":"8","author":"J Zhang","year":"2018","unstructured":"Zhang J, Hu Y, Foley C et al (2018) Exploring Ugi-Azide four-component reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance. Sci Rep 8:4653. https:\/\/doi.org\/10.1038\/s41598-018-22875-9","journal-title":"Sci Rep"},{"key":"5611_CR281","doi-asserted-by":"publisher","first-page":"16704","DOI":"10.1074\/jbc.M110.102533","volume":"285","author":"K Wunderlich","year":"2010","unstructured":"Wunderlich K, Juozapaitis M, M\u00e4nz B et al (2010) Limited compatibility of polymerase subunit interactions in influenza A and B viruses. J Biol Chem 285:16704\u201316712. https:\/\/doi.org\/10.1074\/jbc.M110.102533","journal-title":"J Biol Chem"},{"key":"5611_CR282","doi-asserted-by":"publisher","first-page":"105980","DOI":"10.1016\/j.antiviral.2024.105980","volume":"230","author":"A Bonomini","year":"2024","unstructured":"Bonomini A, Zhang J, Ju H et al (2024) Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo. Antiviral Res 230:105980. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105980","journal-title":"Antiviral Res"},{"key":"5611_CR283","doi-asserted-by":"publisher","first-page":"7801","DOI":"10.1128\/JVI.00724-07","volume":"81","author":"A Ghanem","year":"2007","unstructured":"Ghanem A, Mayer D, Chase G et al (2007) Peptide-mediated interference with influenza A virus polymerase. J Virol 81:7801\u20137804. https:\/\/doi.org\/10.1128\/JVI.00724-07","journal-title":"J Virol"},{"key":"5611_CR284","doi-asserted-by":"publisher","first-page":"e7517","DOI":"10.1371\/journal.pone.0007517","volume":"4","author":"K Wunderlich","year":"2009","unstructured":"Wunderlich K, Mayer D, Ranadheera C et al (2009) Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS ONE 4:e7517. https:\/\/doi.org\/10.1371\/journal.pone.0007517","journal-title":"PLoS ONE"},{"key":"5611_CR285","doi-asserted-by":"publisher","first-page":"105449","DOI":"10.1016\/j.antiviral.2022.105449","volume":"208","author":"K Radilov\u00e1","year":"2022","unstructured":"Radilov\u00e1 K, Zima V, Kr\u00e1\u013e M et al (2022) Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase PA-PB1 subunit interaction. Antiviral Res 208:105449. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105449","journal-title":"Antiviral Res"},{"key":"5611_CR286","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ymeth.2011.08.007","volume":"55","author":"G Chase","year":"2011","unstructured":"Chase G, Wunderlich K, Reuther P, Schwemmle M (2011) Identification of influenza virus inhibitors which disrupt of viral polymerase protein-protein interactions. Methods 55:188\u2013191. https:\/\/doi.org\/10.1016\/j.ymeth.2011.08.007","journal-title":"Methods"},{"key":"5611_CR287","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/febs.12107","volume":"280","author":"C Li","year":"2013","unstructured":"Li C, Ba Q, Wu A et al (2013) A peptide derived from the C-terminus of PB1 inhibits influenza virus replication by interfering with viral polymerase assembly. FEBS J 280:1139\u20131149. https:\/\/doi.org\/10.1111\/febs.12107","journal-title":"FEBS J"},{"key":"5611_CR288","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.antiviral.2015.11.005","volume":"125","author":"S Yuan","year":"2016","unstructured":"Yuan S, Chu H, Zhao H et al (2016) Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase. Antiviral Res 125:34\u201342. https:\/\/doi.org\/10.1016\/j.antiviral.2015.11.005","journal-title":"Antiviral Res"},{"key":"5611_CR289","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.antiviral.2016.11.005","volume":"137","author":"S Yuan","year":"2017","unstructured":"Yuan S, Chu H, Ye J et al (2017) Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface. Antiviral Res 137:58\u201366. https:\/\/doi.org\/10.1016\/j.antiviral.2016.11.005","journal-title":"Antiviral Res"},{"key":"5611_CR290","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.1128\/JVI.00494-16","volume":"90","author":"M Mart\u00ednez-Alonso","year":"2016","unstructured":"Mart\u00ednez-Alonso M, Hengrung N, Fodor E (2016) RNA-free and ribonucleoprotein-associated influenza virus polymerases directly bind the serine-5-phosphorylated carboxyl-terminal domain of host RNA polymerase II. J Virol 90:6014\u20136021. https:\/\/doi.org\/10.1128\/JVI.00494-16","journal-title":"J Virol"},{"key":"5611_CR291","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/rmv.575","volume":"18","author":"K Nagata","year":"2008","unstructured":"Nagata K, Kawaguchi A, Naito T (2008) Host factors for replication and transcription of the influenza virus genome. Rev Med Virol 18:247\u2013260. https:\/\/doi.org\/10.1002\/rmv.575","journal-title":"Rev Med Virol"},{"key":"5611_CR292","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1084\/jem.98.3.229","volume":"98","author":"I Tamm","year":"1953","unstructured":"Tamm I, Folkers K, Horsfall FL (1953) Inhibition of influenza virus multiplication by alkyl derivatives of benzimidazole. II. Measurement of inhibitory activity by hemagglutination titrations. J Exp Med 98:229\u2013243. https:\/\/doi.org\/10.1084\/jem.98.3.229","journal-title":"J Exp Med"},{"key":"5611_CR293","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1016\/j.vaccine.2012.04.085","volume":"30","author":"EC Hutchinson","year":"2012","unstructured":"Hutchinson EC, Fodor E (2012) Nuclear import of the influenza A virus transcriptional machinery. Vaccine 30:7353\u20137358. https:\/\/doi.org\/10.1016\/j.vaccine.2012.04.085","journal-title":"Vaccine"},{"key":"5611_CR294","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.antiviral.2019.02.003","volume":"164","author":"G Mohl","year":"2019","unstructured":"Mohl G, Liddle N, Nygaard J et al (2019) Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5. Antiviral Res 164:81\u201390. https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.003","journal-title":"Antiviral Res"},{"key":"5611_CR295","doi-asserted-by":"publisher","first-page":"e0167221","DOI":"10.1371\/journal.pone.0167221","volume":"11","author":"O Perwitasari","year":"2016","unstructured":"Perwitasari O, Johnson S, Yan X et al (2016) Antiviral efficacy of verdinexor in vivo in two animal models of influenza A virus infection. PLoS ONE 11:e0167221. https:\/\/doi.org\/10.1371\/journal.pone.0167221","journal-title":"PLoS ONE"},{"key":"5611_CR296","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/35060098","volume":"3","author":"S Pleschka","year":"2001","unstructured":"Pleschka S, Wolff T, Ehrhardt C et al (2001) Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade. Nat Cell Biol 3:301\u2013305. https:\/\/doi.org\/10.1038\/35060098","journal-title":"Nat Cell Biol"},{"key":"5611_CR297","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/j.1462-5822.2007.00902.x","volume":"9","author":"I Mazur","year":"2007","unstructured":"Mazur I, Wurzer WJ, Ehrhardt C et al (2007) Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol 9:1683\u20131694. https:\/\/doi.org\/10.1111\/j.1462-5822.2007.00902.x","journal-title":"Cell Microbiol"},{"key":"5611_CR298","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","volume":"92","author":"K Droebner","year":"2011","unstructured":"Droebner K, Pleschka S, Ludwig S, Planz O (2011) Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res 92:195\u2013203. https:\/\/doi.org\/10.1016\/j.antiviral.2011.08.002","journal-title":"Antiviral Res"},{"key":"5611_CR299","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fimmu.2018.00320","volume":"9","author":"X Chen","year":"2018","unstructured":"Chen X, Liu S, Goraya MU et al (2018) Host immune response to influenza A virus infection. Front Immunol 9:320. https:\/\/doi.org\/10.3389\/fimmu.2018.00320","journal-title":"Front Immunol"},{"key":"5611_CR300","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1126\/science.1132505","volume":"314","author":"V Hornung","year":"2006","unstructured":"Hornung V, Ellegast J, Kim S et al (2006) 5\u2032-Triphosphate RNA is the ligand for RIG-I. Science 314:994\u2013997. https:\/\/doi.org\/10.1126\/science.1132505","journal-title":"Science"},{"key":"5611_CR301","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.omtn.2020.01.025","volume":"19","author":"N Singh","year":"2020","unstructured":"Singh N, Ranjan P, Cao W et al (2020) A dual-functioning 5\u2032-PPP-NS1shRNA that activates a RIG-I antiviral pathway and suppresses Influenza NS1. Mol Ther Nucleic Acids 19:1413\u20131422. https:\/\/doi.org\/10.1016\/j.omtn.2020.01.025","journal-title":"Mol Ther Nucleic Acids"},{"key":"5611_CR302","doi-asserted-by":"publisher","first-page":"10172","DOI":"10.1073\/pnas.0914561107","volume":"107","author":"KV Chakravarthy","year":"2010","unstructured":"Chakravarthy KV, Bonoiu AC, Davis WG et al (2010) Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc Natl Acad Sci U S A 107:10172\u201310177. https:\/\/doi.org\/10.1073\/pnas.0914561107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR303","doi-asserted-by":"publisher","first-page":"10359","DOI":"10.1128\/JVI.00665-12","volume":"86","author":"L Lin","year":"2012","unstructured":"Lin L, Liu Q, Berube N et al (2012) 5\u2032-Triphosphate-short interfering RNA: potent inhibition of influenza A virus infection by gene silencing and RIG-I activation. J Virol 86:10359\u201310369. https:\/\/doi.org\/10.1128\/JVI.00665-12","journal-title":"J Virol"},{"key":"5611_CR304","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1128\/JVI.02202-15","volume":"90","author":"S Pattabhi","year":"2015","unstructured":"Pattabhi S, Wilkins CR, Dong R et al (2015) Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR Pathway. J Virol 90:2372\u20132387. https:\/\/doi.org\/10.1128\/JVI.02202-15","journal-title":"J Virol"},{"key":"5611_CR305","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","volume":"413","author":"L Alexopoulou","year":"2001","unstructured":"Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732\u2013738. https:\/\/doi.org\/10.1038\/35099560","journal-title":"Nature"},{"key":"5611_CR306","doi-asserted-by":"publisher","first-page":"11416","DOI":"10.1128\/JVI.01410-12","volume":"86","author":"J Zhao","year":"2012","unstructured":"Zhao J, Wohlford-Lenane C, Zhao J et al (2012) Intranasal treatment with poly(I\u2022C) protects aged mice from lethal respiratory virus infections. J Virol 86:11416\u201311424. https:\/\/doi.org\/10.1128\/JVI.01410-12","journal-title":"J Virol"},{"key":"5611_CR307","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.679511","volume":"12","author":"AA Andreev-Andrievskiy","year":"2021","unstructured":"Andreev-Andrievskiy AA, Zinovkin RA, Mashkin MA et al (2021) Gene expression pattern of Peyer\u2019s patch lymphocytes exposed to kagocel suggests pattern-recognition receptors mediate its action. Front Pharmacol 12:679511. https:\/\/doi.org\/10.3389\/fphar.2021.679511","journal-title":"Front Pharmacol"},{"key":"5611_CR308","doi-asserted-by":"publisher","first-page":"e49049","DOI":"10.1371\/journal.pone.0049049","volume":"7","author":"L Mart\u00ednez-Gil","year":"2012","unstructured":"Mart\u00ednez-Gil L, Ayllon J, Ortigoza MB et al (2012) Identification of small molecules with type I interferon inducing properties by high-throughput screening. PLoS ONE 7:e49049. https:\/\/doi.org\/10.1371\/journal.pone.0049049","journal-title":"PLoS ONE"},{"key":"5611_CR309","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/095632020001100504","volume":"11","author":"S Yasuda","year":"2000","unstructured":"Yasuda S, Huffman JH, Smee DF et al (2000) Spectrum of virus inhibition by consensus interferon YM643. Antivir Chem Chemother 11:337\u2013341. https:\/\/doi.org\/10.1177\/095632020001100504","journal-title":"Antivir Chem Chemother"},{"key":"5611_CR310","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/jir.2010.0071","volume":"31","author":"E Haasbach","year":"2011","unstructured":"Haasbach E, Droebner K, Vogel AB, Planz O (2011) Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo. J Interferon Cytokine Res 31:515\u2013525. https:\/\/doi.org\/10.1089\/jir.2010.0071","journal-title":"J Interferon Cytokine Res"},{"key":"5611_CR311","doi-asserted-by":"publisher","first-page":"1323560","DOI":"10.3389\/fimmu.2023.1323560","volume":"14","author":"F Rashid","year":"2023","unstructured":"Rashid F, Xie Z, Li M et al (2023) Roles and functions of IAV proteins in host immune evasion. Front Immunol 14:1323560. https:\/\/doi.org\/10.3389\/fimmu.2023.1323560","journal-title":"Front Immunol"},{"key":"5611_CR312","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/nsb1197-896","volume":"4","author":"J Liu","year":"1997","unstructured":"Liu J, Lynch PA, Chien CY et al (1997) Crystal structure of the unique RNA-binding domain of the influenza virus NS1 protein. Nat Struct Biol 4:896\u2013899. https:\/\/doi.org\/10.1038\/nsb1197-896","journal-title":"Nat Struct Biol"},{"key":"5611_CR313","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.chom.2009.04.006","volume":"5","author":"MU Gack","year":"2009","unstructured":"Gack MU, Albrecht RA, Urano T et al (2009) Influenza A Virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA Sensor RIG-I. Cell Host Microbe 5:439\u2013449. https:\/\/doi.org\/10.1016\/j.chom.2009.04.006","journal-title":"Cell Host Microbe"},{"key":"5611_CR314","doi-asserted-by":"publisher","first-page":"e1003059","DOI":"10.1371\/journal.ppat.1003059","volume":"8","author":"R Rajsbaum","year":"2012","unstructured":"Rajsbaum R, Albrecht RA, Wang MK et al (2012) Species-specific inhibition of RIG-I ubiquitination and IFN induction by the Influenza A Virus NS1 protein. PLoS Pathog 8:e1003059. https:\/\/doi.org\/10.1371\/journal.ppat.1003059","journal-title":"PLoS Pathog"},{"key":"5611_CR315","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/s1097-2765(00)80099-4","volume":"1","author":"ME Nemeroff","year":"1998","unstructured":"Nemeroff ME, Barabino SM, Li Y et al (1998) Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3\u2019end formation of cellular pre-mRNAs. Mol Cell 1:991\u20131000. https:\/\/doi.org\/10.1016\/s1097-2765(00)80099-4","journal-title":"Mol Cell"},{"key":"5611_CR316","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/s0042-6822(02)00127-7","volume":"307","author":"DL Noah","year":"2003","unstructured":"Noah DL, Twu KY, Krug RM (2003) Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3\u2019 end processing of cellular pre-mRNAS. Virology 307:386\u2013395. https:\/\/doi.org\/10.1016\/s0042-6822(02)00127-7","journal-title":"Virology"},{"key":"5611_CR317","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/cmi.12005","volume":"14","author":"S Gao","year":"2012","unstructured":"Gao S, Song L, Li J et al (2012) Influenza A virus-encoded NS1 virulence factor protein inhibits innate immune response by targeting IKK. Cell Microbiol 14:1849\u20131866. https:\/\/doi.org\/10.1111\/cmi.12005","journal-title":"Cell Microbiol"},{"key":"5611_CR318","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/1087057111431488","volume":"17","author":"EJ Cho","year":"2012","unstructured":"Cho EJ, Xia S, Ma L-C et al (2012) Identification of influenza virus inhibitors targeting NS1A utilizing fluorescence polarization-based high-throughput assay. J Biomol Screen 17:448\u2013459. https:\/\/doi.org\/10.1177\/1087057111431488","journal-title":"J Biomol Screen"},{"key":"5611_CR319","doi-asserted-by":"publisher","first-page":"14659","DOI":"10.1074\/jbc.RA118.004012","volume":"293","author":"AB Kleinpeter","year":"2018","unstructured":"Kleinpeter AB, Jureka AS, Falahat SM et al (2018) Structural analyses reveal the mechanism of inhibition of influenza virus NS1 by two antiviral compounds. J Biol Chem 293:14659\u201314668. https:\/\/doi.org\/10.1074\/jbc.RA118.004012","journal-title":"J Biol Chem"},{"key":"5611_CR320","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1099\/vir.0.025015-0","volume":"92","author":"MP Walkiewicz","year":"2011","unstructured":"Walkiewicz MP, Basu D, Jablonski JJ et al (2011) Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. J Gen Virol 92:60\u201370. https:\/\/doi.org\/10.1099\/vir.0.025015-0","journal-title":"J Gen Virol"},{"key":"5611_CR321","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1007\/s00894-014-2142-7","volume":"20","author":"H Ai","year":"2014","unstructured":"Ai H, Zhang L, Chang AK et al (2014) Virtual screening of potential inhibitors from TCM for the CPSF30 binding site on the NS1A protein of influenza A virus. J Mol Model 20:2142. https:\/\/doi.org\/10.1007\/s00894-014-2142-7","journal-title":"J Mol Model"},{"key":"5611_CR322","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/jac\/dkt534","volume":"69","author":"MK Nayak","year":"2014","unstructured":"Nayak MK, Agrawal AS, Bose S et al (2014) Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses. J Antimicrob Chemother 69:1298\u20131310. https:\/\/doi.org\/10.1093\/jac\/dkt534","journal-title":"J Antimicrob Chemother"},{"key":"5611_CR323","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41587-021-01173-2","volume":"40","author":"K Garber","year":"2022","unstructured":"Garber K (2022) The PROTAC gold rush. Nat Biotechnol 40:12\u201316. https:\/\/doi.org\/10.1038\/s41587-021-01173-2","journal-title":"Nat Biotechnol"},{"key":"5611_CR324","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21:181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6","journal-title":"Nat Rev Drug Discov"},{"key":"5611_CR325","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","volume":"4","author":"X Sun","year":"2019","unstructured":"Sun X, Gao H, Yang Y et al (2019) PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther 4:64. https:\/\/doi.org\/10.1038\/s41392-019-0101-6","journal-title":"Signal Transduct Target Ther"},{"key":"5611_CR326","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto KM, Kim KB, Kumagai A et al (2001) Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A 98:8554\u20138559. https:\/\/doi.org\/10.1073\/pnas.141230798","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5611_CR327","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A (2021) Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov 20:247\u2013250. https:\/\/doi.org\/10.1038\/d41573-021-00052-4","journal-title":"Nat Rev Drug Discov"},{"key":"5611_CR328","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","volume":"20","author":"D Chirnomas","year":"2023","unstructured":"Chirnomas D, Hornberger KR, Crews CM (2023) Protein degraders enter the clinic\u2014a new approach to cancer therapy. Nat Rev Clin Oncol 20:265\u2013278. https:\/\/doi.org\/10.1038\/s41571-023-00736-3","journal-title":"Nat Rev Clin Oncol"},{"key":"5611_CR329","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1021\/acsbiomedchemau.2c00063","volume":"3","author":"RM Espinoza-Ch\u00e1vez","year":"2023","unstructured":"Espinoza-Ch\u00e1vez RM, Salerno A, Liuzzi A et al (2023) Targeted protein degradation for infectious diseases: from basic biology to drug discovery. ACS Bio Med Chem Au 3:32\u201345. https:\/\/doi.org\/10.1021\/acsbiomedchemau.2c00063","journal-title":"ACS Bio Med Chem Au"},{"key":"5611_CR330","doi-asserted-by":"publisher","first-page":"113814","DOI":"10.1016\/j.ejmech.2021.113814","volume":"226","author":"J Desantis","year":"2021","unstructured":"Desantis J, Mercorelli B, Celegato M et al (2021) Indomethacin-based PROTACs as pan-coronavirus antiviral agents. Eur J Med Chem 226:113814. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113814","journal-title":"Eur J Med Chem"},{"key":"5611_CR331","doi-asserted-by":"publisher","first-page":"116202","DOI":"10.1016\/j.ejmech.2024.116202","volume":"268","author":"J Desantis","year":"2024","unstructured":"Desantis J, Bazzacco A, Eleuteri M et al (2024) Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity. Eur J Med Chem 268:116202. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116202","journal-title":"Eur J Med Chem"},{"key":"5611_CR332","doi-asserted-by":"publisher","first-page":"12858","DOI":"10.3390\/ijms222312858","volume":"22","author":"F Hahn","year":"2021","unstructured":"Hahn F, Hamilton ST, Wangen C et al (2021) Development of a PROTAC-based targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity. Int J Mol Sci 22:12858. https:\/\/doi.org\/10.3390\/ijms222312858","journal-title":"Int J Mol Sci"},{"key":"5611_CR333","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","volume":"10","author":"M de Wispelaere","year":"2019","unstructured":"de Wispelaere M, Du G, Donovan KA et al (2019) Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat Commun 10:3468. https:\/\/doi.org\/10.1038\/s41467-019-11429-w","journal-title":"Nat Commun"},{"key":"5611_CR334","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","volume":"453","author":"K Montrose","year":"2014","unstructured":"Montrose K, Krissansen GW (2014) Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus. Biochem Biophys Res Commun 453:735\u2013740. https:\/\/doi.org\/10.1016\/j.bbrc.2014.10.006","journal-title":"Biochem Biophys Res Commun"},{"key":"5611_CR335","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1038\/s41467-024-49161-9","volume":"15","author":"H-Y Liu","year":"2024","unstructured":"Liu H-Y, Li Z, Reindl T et al (2024) Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism. Nat Commun 15:5179. https:\/\/doi.org\/10.1038\/s41467-024-49161-9","journal-title":"Nat Commun"},{"key":"5611_CR336","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.chembiol.2024.02.004","volume":"31","author":"LA Emert-Sedlak","year":"2024","unstructured":"Emert-Sedlak LA, Tice CM, Shi H et al (2024) PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication. Cell Chem Biol 31:658-668.e14. https:\/\/doi.org\/10.1016\/j.chembiol.2024.02.004","journal-title":"Cell Chem Biol"},{"key":"5611_CR337","doi-asserted-by":"publisher","first-page":"116629","DOI":"10.1016\/j.ejmech.2024.116629","volume":"275","author":"S Cheng","year":"2024","unstructured":"Cheng S, Feng Y, Li W et al (2024) Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses. Eur J Med Chem 275:116629. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116629","journal-title":"Eur J Med Chem"},{"key":"5611_CR338","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41587-022-01381-4","volume":"40","author":"L Si","year":"2022","unstructured":"Si L, Shen Q, Li J et al (2022) Generation of a live attenuated influenza A vaccine by proteolysis targeting. Nat Biotechnol 40:1370\u20131377. https:\/\/doi.org\/10.1038\/s41587-022-01381-4","journal-title":"Nat Biotechnol"},{"key":"5611_CR339","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/s41467-022-29690-x","volume":"13","author":"J Zhao","year":"2022","unstructured":"Zhao J, Wang J, Pang X et al (2022) An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA. Nat Commun 13:2079. https:\/\/doi.org\/10.1038\/s41467-022-29690-x","journal-title":"Nat Commun"},{"key":"5611_CR340","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.chom.2023.05.030","volume":"31","author":"N Zhao","year":"2023","unstructured":"Zhao N, Ho JSY, Meng F et al (2023) Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics. Cell Host Microbe 31:1154-1169.e10. https:\/\/doi.org\/10.1016\/j.chom.2023.05.030","journal-title":"Cell Host Microbe"},{"key":"5611_CR341","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.1021\/acs.jmedchem.1c02013","volume":"65","author":"H Li","year":"2022","unstructured":"Li H, Wang S, Ma W et al (2022) Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders. J Med Chem 65:7154\u20137169. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02013","journal-title":"J Med Chem"},{"key":"5611_CR342","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1021\/acs.jmedchem.4c00131","volume":"67","author":"X Ma","year":"2024","unstructured":"Ma X, Wang X, Chen F et al (2024) Novel acyl thiourea-based hydrophobic tagging degraders exert potent anti-influenza activity through two distinct endonuclease polymerase acidic-targeted degradation pathways. J Med Chem 67:8791\u20138816. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00131","journal-title":"J Med Chem"},{"key":"5611_CR343","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.cellin.2022.100030","volume":"1","author":"Z Xu","year":"2022","unstructured":"Xu Z, Liu X, Ma X et al (2022) Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus. Cell Insight 1:100030. https:\/\/doi.org\/10.1016\/j.cellin.2022.100030","journal-title":"Cell Insight"},{"key":"5611_CR344","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","volume":"7","author":"M He","year":"2022","unstructured":"He M, Cao C, Ni Z et al (2022) PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther 7:181. https:\/\/doi.org\/10.1038\/s41392-022-00999-9","journal-title":"Signal Transduct Target Ther"},{"key":"5611_CR345","doi-asserted-by":"publisher","first-page":"CD001169","DOI":"10.1002\/14651858.CD001169","volume":"2000","author":"TO Jefferson","year":"2000","unstructured":"Jefferson TO, Demicheli V, Deeks JJ, Rivetti D (2000) Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev 2000:CD001169. https:\/\/doi.org\/10.1002\/14651858.CD001169","journal-title":"Cochrane Database Syst Rev"},{"key":"5611_CR346","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1517\/14656566.6.14.2493","volume":"6","author":"J Oxford","year":"2005","unstructured":"Oxford J (2005) Oseltamivir in the management of influenza. Expert Opin Pharmacother 6:2493\u20132500. https:\/\/doi.org\/10.1517\/14656566.6.14.2493","journal-title":"Expert Opin Pharmacother"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05611-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:39:56Z","timestamp":1739439596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05611-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":346,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5611"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05611-1","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors give consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"75"}}